What are Datasets?

Datasets are defined file collections, whose access is governed by a Data Access Committee (DAC).

Total number of Datasets: 3632
Displaying 1 - 3632

Dataset Accession Description Technologysort descending Samples File Types
EGAD00000000019 840 families where both parents have been genotyped together with the child with severe malaria 0
EGAD00000000024 WTCCC2 project samples from National Blood Donors (NBS) Cohort 1
EGAD00001000002 Massive genomic rearrangement acquired in a single catastrophic event during cancer development 11 srf
EGAD00000000023 WTCCC2 project samples from National Blood Donors (NBS) Cohort 1
EGAD00001001856 100 other
EGAD00010000853 VeraCode GoldenGate GT Assay technology 147
EGAD00010000823 Results of SNP arrays on synchronous CRC samples 1
EGAD00001000277 High Quality Variant Call files, generated by bioscope, converted to vcf format. Complete dataset for all 300 samples. 300 vcf
EGAD00001000001 Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma 18 srf
EGAD00000000020 685 families where both parents have been genotyped together with the child with severe malaria 0
EGAD00010000458 Controls using 450K DNA methylation 151
EGAD00001000202 Neuroblastoma samples (Analyses_vcf files) 204 vcf
EGAD00001000308 Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing 1 bam
EGAD00000000017 Cord blood control samples from Gambia 0
EGAD00000000018 Severe malaria cases from Gambia 0
EGAD00000000029 Aggregate results from a case-control study on stroke and ischemic stroke. 19,602
EGAD00001000262 OICR PANCREATIC CANCER DATASET 4 bam
EGAD00001000276 OICR PANCREATIC CANCER DATASET 2 10 bam
EGAD00001000428 204 individuals were genotyped with the Illumina 2.5M Omni chip. Filtered genotypes were imputed into the 1000 genomes project European panel SNPs. Beagle R2 is indicated in VCF files for further filtering. See Materials and Methods in publication for details. 204 vcf
EGAD00010000456 Leukemia samples using 450K DNA methylation 800
EGAD00001000395 Noninvasive Prenatal Molecular Karyotyping from Maternal Plasma 1 bam
EGAD00010000460 GENCORD2 DNA methylation 294
EGAD00001000623 This VCF contains the full sequence data post QC. This consists of 41,911 individuals. All polymorphic sites are present in this VCF. 41,911 vcf
EGAD00001000645 ICGC MMML-seq Data Freeze July 2013 whole genome sequencing 42 bam
EGAD00001000648 ICGC MMML-seq Data Freeze July 2013 transcriptome sequencing 31 bam
EGAD00001000665 Illumina HiSeq sequence data (with >30x coverage) were aligned to the hg19 human reference genome assembly using BWA (Li and Durbin, 2009); duplicate reads were removed from the final BAM file. No realignment or recalibration was performed. Sample derived from secondary myelodysplastic syndrome (MDS), arising after treatment for medulloblastoma in an 11-year old female Li-Fraumeni syndrome case (LFS-MB1; Rausch et al., 2012; matching WGS data available under EGAS00001000085). 1 bam
EGAD00001000618 1204 Sardinian males 1,195 bam
EGAD00001000666 HSC73_clone: Bone marrow mononuclear cells from the healthy 73 years old female were thawed and labeled with Alexa-Fluor 488-conjugated anti-CD34 (581, Biolegend), Alexa-Fluor 700-conjugated anti-CD38 (HIT2, eBioscience), a cocktail of APC-conjugated lineage antibodies consisting of anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti-CD11b (ICRF44), anti-CD20 (2H7), anti-CD56 (B159, all BD Biosciences), anti-CD14 (61D3), anti-CD19 (HIB19) and anti-CD235a (HIR2, all eBiocience) and 1 micro-gram/ml propidium iodide (Sigma). Using a BD FACSAria cell sorter, single Lin-CD34+CD38-PI- cells were individually sorted into low-adhesion 96-well tissue culture plates (Corning) containing 100micro-litre of StemSpan Serum-Free Expansion Medium (Stemcell technologies) supplemented with 100ng/ml of human SCF and FLT-3L, 50ng/ml of human TPO, 20ng/ml of human IL-3, IL-6 and G-CSF (all cytokines from Peprotech) and 50U/ml of penicillin and 50μg/ml of streptomycin (Sigma). Cells were incubated at 37 degrees C in a humidified atmosphere with 5% CO2 in air. After 5 days in culture, another 100micro litres of cytokine-containing medium were added. 13 days after seeding, clones B6 and G2 had expanded to approx. 105 cells and were selected for whole genome sequencing (2x101bp, paired-end, Illumina HiSeq2500) after tagmentation-based library preparation (see Extended Experimental Procedures) for clone B6 and standard library preparation for clone G2. For germline-control ~106 unsorted bone marrow mononuclear cells from the same donor were used for sequencing. An average of 30-fold sequence coverage for each the clones and the matching control were obtained. L4clone: A progenitor cell clone was raised from a peripheral blood sample of the 39 year old healthy female. Frozen peripheral blood mononuclear cells (PBMCs) were isolated from 2 ml heparinised peripheral blood via Ficoll Paque density centrifugation. A methylcellulose assay was performed as described earlier (Weisse et al., 2012). In brief, non-adherent mononuclear cells were incubated in the presence of the recombinant human cytokines IL-3, IL-5 and GM-CSF (R&D systems) over 14 days to induce colony formation. Colonies were detected under an inverted light microscope, and plucked by a pipette when colonies had approximately 10,000 cells/CFU. Each colony was washed three times in PBS and finally frozen as a cell pellet in -80 degrees C. Genomic DNA was isolated using the QIAamp DNA micro kit according to the instructions of the manufacturer (Qiagen, Hilden, Germany). Whole genome sequencing (2x101bp, paired-end, Illumina HiSeq2500) was performed for colony 4 after tagmentation-based library preparation and resulted in 15-fold sequence coverage for each the colony and the matching whole blood. 5 bam
EGAD00001000664 Whole Genome Seq: Illumina HiSeq sequence data (with >30x coverage) were aligned to the hg19 human reference genome assembly using BWA (Li and Durbin, 2009); duplicate reads were removed from the final BAM file. No realignment or recalibration was performed. Paired-end RNA sequencing reads were mapped to the hg19 assembly of the human reference genome using BWA. Each ChIP-seq library was sequenced with two complete lanes on the Illumina HiSeq 2500 in the 101-bases paired-end rapid mode and aligned to hg19 using bwa. This resulted in the following coverage values (genome-wide, after deduplication, including all uniquely mapping reads): GBM103 macroH2A1: 17x H3K36me3: 20x MB59 macroH2A1: 11x H3K36me3: 11x 7 bam
EGAD00001000691 Whole genome sequencing data from Illumina platform were generated using 10 human cancer cell lines and 2 primary tumor samples. Nine of these samples contained fragments of human papillomavirus (HPV). 12 bai,bam
EGAD00010000702 SNP-chip genotyping data for one proband in the DDD study (Ref : Carvalho AJHG 2015) 0
EGAD00001000693 The genetic consequences of cellular transformation by Epstein-Barr-Virus were assessed by comparing whole genome sequences of the original genome (before transformation) and the genome after transformation. 2 bam,vcf
EGAD00001000660 Analysis .bam files from HiSeq sequencing of Australian ICGC PDAC study samples, submitted 20130826 353 bam
EGAD00001000650 ICGC MMML-seq Data Freeze July 2013 miRNA sequencing 52 bam
EGAD00001000717 Dataset of CageKid Tumor DNA samples 95 bam
EGAD00001000718 Dataset of CageKid Tumor RNA samples 91 bam
EGAD00001000719 Dataset of CageKid Normal RNA samples 45 bam
EGAD00001000709 Dataset of CageKid Blood DNA samples 95 bam
EGAD00001000714 102 bam
EGAD00001000720 Dataset of CageKid tumor-normal paired RNA samples 90 bam
EGAD00001001355 DDD DATAFREEZE 2013-12-18: 1133 trios - VCF files (Ref: DDD Nature 2015) 3,335 readme_file,tab,vcf
EGAD00001000743 These files contain a total of 20.4M SNVs and the complete information output by the GATK UnifiedGenotyper v1.4 on all 767 GoNL samples. These calls are not trio-aware and all genotypes were reported regardless of their quality. Both filtered and passing calls are reported in these files. Filtered calls include (1) calls failing our VQSR threshold and (2) calls in the GoNL inaccessible genome. 767 vcf
EGAD00001000744 The samples in this panel come from 250 families: 248 parents-child trios and 2 parent-child duos. As the children do not provide additional haplotypes or population information, they were excluded from the panel. The samples present in the release are composed of 248 couples, 2 single individuals and 1 sample composed from the 2 haplotypes from the duo's children transmitted by their missing parent. The composed sample is named gonl-220c_223c. The files contain a total of 18.9M SNVs and 1.1M INDELs in autosomal chromosomes. They were generated by phasing/imputing the SNVs (a) and INDELs (b) using MVNCall. Only sites passing filters are reported. Sites filtered as part of the GoNL inaccessible genome were kept (but flagged as filtered) and still may contain true positive calls but should be used with care as they are located in parts of the genome that are less well captured (systematic under or over-covered or low-mapping quality) 499 vcf
EGAD00010000574 Pleuropulmonary blastoma samples using 250K 14
EGAD00001000777 Dataset contains MeDIP-Seq, MRE-Seq and H3K4me3 ChIP-Seq data on 5 GBM patients. 16 bam
EGAD00001000698 Illumina HiSeq sequence data (with >80x coverage) were aligned to the hg19 human reference genome assembly using BWA (Li and Durbin, 2009); duplicate reads were removed from the final BAM file. No realignment or recalibration was performed. The whole exome sequencing data of 20 SHH medulloblastomas from phs000504.v1.p1 dataset has been used in our study on SHH medulloblastomas: http://www.ncbi.nlm.nih.gov/projects/gap/cgi- bin/study.cgi?study_id=phs000504.v1.p1 4 bam
EGAD00001000816 ICGC medulloblastoma whole genome sequencing data, ICGC release 16 44 bam
EGAD00001000814 Whole genome alignments of DIPG patients 40 bam,phenotype_file
EGAD00001000818 Quiescent Sox2+ cells drive hierarchical growth and relapse in Sonic hedgehog subgroup medulloblastoma 4 bam
EGAD00010000534 Illumina HumanMethylation450 BeadChip 0
EGAD00010000528 Illumina HumanHT-12 v4 array 0
EGAD00010000532 Illumina Human Omni1-Quad SNP genotyping array 0
EGAD00010000738 Generation Scotland APOE data 18,336
EGAD00001000789 UK10K_COHORT_ALSPAC REL-2012-06-02: Phenotype data 1,927 phenotype_file,readme_file
EGAD00001000790 UK10K_COHORT_TWINSUK REL-2012-06-02: Phenotype data 1,854 phenotype_file,readme_file
EGAD00010000554 SNP 6.0 arrays of small cell lung cancer 1,032
EGAD00010000556 SNP 6.0 arrays of small cell lung cancer 0
EGAD00010000298 All cases and controls (Hap300) 13,761
EGAD00010000296 1958BC control samples only (Hap550) 2,224
EGAD00010000294 1958BC control samples only (Hap300) 2,436
EGAD00010000292 All cases and Finnish, Dutch, Italian control samples (Hap300) 10,339
EGAD00010000290 NBS control samples only (Hap550) 2,276
EGAD00010000288 All cases and Finnish, Dutch, Italian control samples (Hap550) 6,313
EGAD00001000874 Indel/point mutation of chondrosarcoma 10 vcf
EGAD00001000781 Whole genome, high coverage, sequencing of 128 Ashkenazi Jewish controls 128 vcf
EGAD00010000566 HipSci - Healthy Normals - Genotyping Array - May 2014 120
EGAD00010000564 HipSci - Healthy Normals - Expression Array - May 2014 120
EGAD00010000568 HipSci - Healthy Normals - Methylation Array - May 2014 0
EGAD00010000570 Imputation-based meta-analysis of severe malaria in Kenya. 3,343
EGAD00010000572 Imputation-based meta-analysis of severe malaria in Gambia. 2,870
EGAD00010000580 Gencode control samples using 550K 217
EGAD00010000736 AAD case and control samples from UK and Norway 117
EGAD00010000578 Gencode case samples using 550K 249
EGAD00001003336 BAM outputs from RSEM (https://deweylab.github.io/RSEM/) analysis of RNASeq sequencing on HiSeq platform of tumour samples from 29 pancreatic neuroendocrine cases. 29
EGAD00001000880 233 bam,vcf
EGAD00010000652 Genotyped samples using Illumina HumanOmni2.5 402
EGAD00010000698 PCGP INF ALL SNP6 0
EGAD00010000682 glioma samples tumor using 250K 0
EGAD00010000688 glioma normal samples using 250K 0
EGAD00010000684 glioma normal samples using cytoscan 0
EGAD00010000686 glioma samples tumor using cytoscan 0
EGAD00010000708 Human samples typed on Illumina Omni 5M 0
EGAD00010000704 610k genotyping imputed on Hapmap 3 and 1000G Phase 1 CEU 714
EGAD00001000158 Subgroup-specific structural variation across 1,000 medulloblastoma genomes 23 bam
EGAD00001001210 Altered translation response to stress by medulloblastoma-associated DDX3X mutations 28 bam
EGAD00001001253 DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. WG sequencing produced ~30-fold (primary tumour, spleen normal)-50-fold (lung metastasis) coverage 3 bam
EGAD00001001252 DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. For WE sequencing we user Hybrid capture (Nimblegen version 3.0) of the lymph node and lung metastases, primary tumour and spleen normal; we generated ~100-fold coverage. 4 bam
EGAD00001001114 DDD DATAFREEZE 2013-12-18: 1133 trios - exome sequence BAM files (Ref: DDD Nature 2015) 3,335 bam,tab
EGAD00010000658 DLBCL 148 SNP 6.0 Cohort 0
EGAD00010000664 Finnish population cohort genotyping_B 340
EGAD00010000712 ATRT genotyping 0
EGAD00010000662 Finnish population cohort genotyping 7,803
EGAD00010000594 SCOOP severe early-onset obesity cases 1,720
EGAD00010000610 Samples from the Greek island of Crete, MANOLIS cohort 221
EGAD00010000596 PCGP Ph-likeALL GEA 837
EGAD00010000598 PCGP Ph-likeALL SNP6 1,724
EGAD00010000604 DNA methylation data using Illumina 450K 2,195
EGAD00001000946 Divergent clonal selection dominates medulloblastoma at recurrence 125 bam
EGAD00010000552 Neuroblastoma samples 130
EGAD00001001001 2 bam
EGAD00001000950 Whole genome sequencing data for ependymomas (5 tumor-control pairs). See Mack, Witt et al. Nature 506(7489):445-50, 2014 (PMID: 24553142). 10 bam
EGAD00001000951 Whole exome sequencing data for ependymomas (42 tumor-control pairs). See Mack, Witt et al. Nature 506(7489):445-50, 2014 (PMID: 24553142). 84 bam
EGAD00010000606 SNP6 data for matched normal samples 8
EGAD00010000608 SNP6 data for seminoma samples 8
EGAD00010000584 WTCCC2 Glaucoma samples using Illumina 670k array 2,765
EGAD00010000602 WTCCC2 Reading and Mathematics ability (RM) samples from UK using the Affymetrix 6.0 array 3,665
EGAD00010000612 Celiac disease North Indian samples using Immunochip 0
EGAD00001001887 Exome sequencing VCF files describing mutations during glioma progression. 82 vcf
EGAD00010000858 Achalasia cases & controls 8,151
EGAD00001001860 19 vcf
EGAD00010000616 HumanOmni1-Quad genotyping array 230
EGAD00010000618 Ischemic stroke cases 3,682
EGAD00010000620 Controls 3,683
EGAD00001001034 Whole genome data (Complete genomics platform) for the study EGAS00001000824 24 other
EGAD00001001038 We mapped the data to the UCSC human reference genome build 37 using BWA 0.5.9-r16. We first mapped each read pair separately using bwa aln. Then we used bwa sampe to map the paired reads together to a BAM9 file. The BAM file was then sorted by genomic position and indexed using PicardTools-1.32 SortSam. To prevent PCR artifacts from influencing the downstream analysis of our data, we used Picard to mark the duplicate reads, which were ignored in downstream analysis. We used GATK IndelRealigner on our data around known indels (from 1KG Pilot). The IndelRealigner creates all possible read alignments using the source and computes the likelihood of the data containing the indel based on the read pileup. Whenever the maximum likelihood contains an indel, the reads are realigned accordingly. Each base is associated with a phred-scaled base quality score. Calibration of Phred scores is crucial as they are used in some of the downstream analysis models. We used GATK to recalibrate the base qualities with respect to (i) the base cycle, (ii) original quality score, and (iii) dinucleotide context. To minimize issues stemming from mapping problems around indels, we decided to undergo a second round of indel realignment using the GATK IndelRealigner by family rather than by individual. For this second round, we considered two sources of possible indels: 1KG Phase 1 indels and indels aligned by BWA in the GoNL data. 769 bam
EGAD00010000626 A new beta-globin mutation responsible of a beta-thalassemia (HbVar database ID 2928) was observed in 8 unrelated French families. The mutation carriers originated from Nord-Pas-de-Calais, a Northern French region where the chief town is Lille. 5 unrelated mutation carriers were genotyped for a set of 12 microsatellites from chromosome 11, around the beta-globin gene. Among the 5 mutation carriers, 4 were genotyped for 97 European Ancestry Informative SNPs (EAIMs). 37
EGAD00010000624 A new beta-globin mutation responsible of a beta-thalassemia (HbVar database ID 2928) was observed in 8 unrelated French families. The mutation carriers originated from Nord-Pas-de-Calais, a Northern French region where the chief town is Lille. 5 unrelated mutation carriers were genotyped for a set of 12 microsatellites from chromosome 11, around the beta-globin gene. Among the 5 mutation carriers, 4 were genotyped for 97 European Ancestry Informative SNPs (EAIMs). 0
EGAD00010000630 The TEENAGE study target population comprised adolescent students aged 13–15 years attending the first three classes of public secondary schools located in the wider Athens area of Attica. 436
EGAD00010000634 WTCCC2 People of the British Isles (POBI) samples using Affymetrix 6.0 array 2,930
EGAD00010000632 WTCCC2 People of the British Isles (POBI) samples using Illumina 1.2M array 2,912
EGAD00010000628 The TEENAGE study target population comprised adolescent students aged 13–15 years attending the first three classes of public secondary schools located in the wider Athens area of Attica. 0
EGAD00010000642 CLL Expression Array 144
EGAD00010000644 Affymetrix SNP6.0 cancer cell line exome sequencing data 1,022
EGAD00010000646 DNA methylation analysis of 35 prostate tumor and 6 normal prostate samples 41
EGAD00010000648 nccRCC tumor/normal genotypes 0
EGAD00010000614 40 Druze Trios 120
EGAD00001000845 44 bam
EGAD00001001080 MDS patients 5 bam
EGAD00001001081 Healthy reference samples 3 bam
EGAD00001001303 The dataset for the PROP1 study consists of samples of patients with combined pituitary hormone deficiency due to two most prevalent mutations in the PROP1 gene (c.301_302delGA and c.150delA) and healthy relatives and controls. All subjects were genotyped for 21 single nucleotide polymorphisms surrounding the PROP1 gene in order to assess the potential ancestral origin of the respective mutations. The genotype data are displayed in the vcf format. 328 vcf
EGAD00001001329 Aligned Sequence (bam format), Duplicates removed 28 bam
EGAD00010000718 BLUEPRINT Gene expression of different B-cell subpopulations 42
EGAD00010000716 BLUEPRINT DNA Methylation of different B-cell subpopulations 35
EGAD00001001075 miRNA-seq Cohort of 15 Benign Centroblasts 15 bam
EGAD00001001073 miRNA-seq Cohort of 140 Formalin Fixed Paraffin Embedded Diffuse Large B-cell Lymphoma Patient Samples 140 bam
EGAD00001001074 miRNA-seq Cohort of 92 Fresh Frozen Diffuse Large B-cell Lymphoma Patient Samples 92 bam
EGAD00001001087 RNAseq BAM files for the Skin samples of the EUROBATS project. 672 bai,bam
EGAD00001001086 These analysis are the BAM files for the LCLs samples of the EUROBATS samples. 765 bai,bam
EGAD00001001088 RNAseq BAM files for the blood samples of the EUROBATS project 391 bai,bam
EGAD00001001089 RNAseq BAM files for the Fat samples of the EUROBATS project 685 bai,bam
EGAD00010000656 Case samples using SNP 6.0 Array 0
EGAD00010000654 Control samples using SNP 6.0 Arrays 0
EGAD00010000650 Genotypes from Omni2.5 chip 1,213
EGAD00001003345 exome sequence data for 57 HIV elite long term non-progressors and rapid progressors. Complete dataset of improved BAMs mapped to hs37d5 and including phenotype information. 57
EGAD00010000847 Genotyping using Affymetrix SNP6.0 49
EGAD00001001359 Dataset contains Exome-seq and RNA-seq from 2 GBM patients, as well as RNA-seq from the derived cultured cells (GNS). 6 bam
EGAD00010000674 ELSA genome-wide genotypes, excluding estimated related individuals. There are 3 files: .fam, .bim, .bed 7,412
EGAD00010000676 ELSA genome-wide genotypes, including estimated related individuals. There are 3 files: .fam, .bim, .bed 7,452
EGAD00001001126 340 other
EGAD00001000963 Exome sequencing of sporadic schwannomatosis patients 16 bam
EGAD00001000964 Low-coverage whole genome sequencing of sporadic schwannomatosis patients 16 bam
EGAD00001001218 10 bam
EGAD00001001217 15 bam
EGAD00010000694 HCC array for cnv 55
EGAD00010000771 HipSci - Healthy Normals - Methylation Array - April 2015 0
EGAD00001001435 Aligned whole genome bisulfite sequencing data for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 30 bam
EGAD00010000640 WTCCC2 Visceral Leishmaniasis samples from Sudanl using Illumina 670k 21
EGAD00010000638 WTCCC2 Visceral Leishmaniasis samples from Indial using Illumina 670k 97
EGAD00010000636 WTCCC2 Visceral Leishmaniasis samples from Brazil using Illumina 670k 119
EGAD00010000696 PCGP ETP ALL SNP6 0
EGAD00001001226 smRNA-Seq assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada as part of the International Human Epigenome Consortium. 28 bam
EGAD00001001228 Whole genome shotgun sequencing assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 27 bam,vcf
EGAD00001001227 Strand-specific mRNA-Seq assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 32 bam
EGAD00001001235 ChIP-Seq (Input) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 48 bam
EGAD00001001240 VCF files of somatic variants from tumor-normal pairs of Asian lung cancer patients 30 vcf
EGAD00010000690 Genome-wide SNP genotyping of African rainforest hunter-gatherers and neighbouring agriculturalists by Illumina HumanOmniExpress 160
EGAD00010000692 Genome-wide DNA methylation epigenotyping of African rainforest hunter-gatherers and neighbouring agriculturalists by Illumina HumanMethylation450 372
EGAD00010000724 Pilot experiment on functional genomics in osteoarthritis (methyl) 0
EGAD00010000730 WTCCC2 Psychosis Endophenotype samples from UK, Germany, Holland, Spain and Australia using the Affymetrix 6.0 array 1
EGAD00001000656 FACS phenotype of 1629 Sardinian samples 1,629 phenotype_file
EGAD00010000710 ATRT genotyping blood 0
EGAD00001000877 Complete WGS and RNA-Seq dataset for Australian ICGC ovarian cancer sequencing project 2014-07-07, representing 93 donors. Sequencing was performed on Illumina HiSeq. Alignment of the lane-level fastq data was performed with bwa (WGS data) and RSEM (transcriptome data). For this dataset lane-level .bam files have been merged and de-duplicated to create a single bam file for each sample type (tumour/normal) for each donor. This dataset supersedes all previous datasets for this study. 331 bam
EGAD00010000722 Pilot experiment on functional genomics in osteoarthritis (coreex) 1
EGAD00010000764 Ovarian tumor samples using Illumina 0
EGAD00001001310 Genome and transcriptome sequence data from a peritoneal mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001001413 DDD DATAFREEZE 2013-12-18: 1133 trios - README, family trios, phenotypes, validated DNMs (Ref: DDD Nature 2015) 3,335 readme_file,tab
EGAD00001001360 The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neuroblastomas showed clonal evolution from the diagnostic tumor with a median of 29 somatic mutations unique to the relapse sample. Eighteen of the 23 relapse tumors (78%) showed RAS-MAPK pathway mutations. Seven events were detected only in the relapse tumor while the others showed clonal enrichment. In neuroblastoma cell lines we also detected a high frequency of activating mutations in the RAS-MAPK pathway (11/18, 61%) and these lesions predicted for sensitivity to MEK inhibition in vitro and in vivo. Our findings provide a rationale for genetic characterization of relapse neuroblastoma and show that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease. 221 other,vcf
EGAD00010000768 Replication data for HipSci normal samples using both HumanCoreExome-12_v1 and HumanOmni2.5-8 BeadChips 0
EGAD00010000766 We have established a mechanism for the collection of postal DNA samples from consenting National Joint Registry for England and Wales (NJR) patients and have carried out genotyping genome-wide in 903 patients with the condition Developmental Dysplasia of the Hip (DDH) on the Illumina CoreExome array 903
EGAD00001001390 Human monocytes from a healthy male blood donor were obtained after written informed consent and anonymised. Library preparation was performed essentially as described in the “Whole‐genome Bisulfite Sequencing for Methylation Analysis (WGBS)” protocol as released by Illumina. The library was sequenced on an Illumina HiSeq2500 using 101 bp paired-end sequencing. Read mapping was done with BWA. 1 bam,readme_file
EGAD00001001941 Variants derived from mapped whole transcriptome RNA-Seq data from 476 human samples of early stage urothelial carcinoma. 476 vcf
EGAD00010000791 Illumina HumanOmni2.5-8 BeadChip 1
EGAD00001000702 Complete set of bam files associated with study EGAS00001000622 190 bam
EGAD00010000787 Epigen-Brasil samples using HumanOmni2.5 6,487
EGAD00010000807 Illumina HumanCoreExome genotyping data from the British Society for Surgery of the Hand Genetics of Dupuytren's Disease consortium (BSSH-GODD consortium) collection 4,201
EGAD00001001466 Whole Genome sequencing. 2 ?g of genomic DNA from each sample was used for the construction of two short-insert paired-end sequencing libraries. Both types of libraries were sequenced in paired-end mode on Illumina GAIIx (2 × 151 bp) using Sequencing kit v4 or Illumina HiSeq2000 (2x101 bp) using TruSeq SBS Kit v3. 300 bam
EGAD00001001464 Exome Sequencing. 3 ?g of genomic DNA from each sample were sheared and used for the construction of a paired-end sequencing library as described in the paired-end sequencing sample preparation protocol provided by Illumina41. Enrichment of exonic sequences was then performed for each library using either the Sure Select Human All Exon 50 Mb or All Exon+UTRs v4 kits following the manufacturer’s instructions (Agilent Technologies). Exon-enriched DNA was pulled down by magnetic beads coated with streptavidin (Invitrogen), followed by washing, elution and 18 additional cycles of amplification of the captured library. Enriched libraries were sequenced (2 × 76 bp) in one lane of an Illumina GAIIx sequencer or in two lanes of a HiSeq2000 when using pools of eight samples. 882 bam
EGAD00001002024 Genome and transcriptome sequence data from an anal rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00010000748 Genotyping using Illumina Human OmniExpress12v1.0 1
EGAD00001001456 1000Genomes imputed data set of 581 cases and 417 controls for male-pattern baldness 1 vcf
EGAD00010000819 Summary statistics from meta-analysis for BP phenotypes 0
EGAD00001001609 Maternal Plasma RNA Sequencing for Genomewide Transcriptomic Profiling and Identification of Pregnancy-Associated Transcripts 14 bam
EGAD00001001616 2 bam
EGAD00001001614 26 bam
EGAD00001001613 10 bam
EGAD00001001615 10 bam
EGAD00010000829 Illumina Infinium 450K array data 70
EGAD00010000827 Illumina Infinium 450K array data 1
EGAD00010000815 ATL tumor samples using Affymetrix 250K SNP array 1
EGAD00010000813 ATL tumor samples using Illumina 450K Methylation array 1
EGAD00010000811 ATL tumor samples using Illumina 610K SNP array 1
EGAD00001001635 Whole genome sequencing detected structural rearrangements of TERT in 17/75 high stage neuroblastoma with 5 cases resulting from chromothripsis. Rearrangements were associated with increased TERT expression and targeted immediate up- and down-stream regions of TERT, placing in 7 cases a super-enhancer close to the breakpoints. TERT rearrangements (23%), ATRX deletions (11%) and MYCN amplifications (37%) identify three almost non-overlapping groups of high stage neuroblastoma, each associated with very poor prognosis. This submission contains all newly sequenced samples only. study_refcenter AMC 42 other
EGAD00001001660 Whole exome sequencing was performed to explore the mutational landscape and potential molecular signature of HPV-positive versus HPV-negative OAC. Four hr-HPV-positive and 8 HPV-negative treatment-naive fresh-frozen OAC tissue specimens and matched normal tissue were analysed to identify somatic genomic mutations 24 bam
EGAD00001001661 Genotype and exome data for an Australian Aboriginal population: a reference panel for health-based research. 72 vcf
EGAD00001002650 Somatic variants called from whole-exome sequencing of meningioma-blood pairs 87 vcf
EGAD00001001663 Low coverage (4x-8x) Illumina HiSeq curated sequence data from 3 African populations from the AGV project; 100 Baganda from Uganda (4x), 100 Zulu from South Africa (4x), and 120 Gumuz, Wolayta, Oromo, Somali and Amhara from Ethiopia (8x). Pre-processed, jointly called and filtered with GATK, refined with Beagle3, phased with SHAPEIT2. 1 vcf
EGAD00001001782 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB8_F 1 other
EGAD00001001785 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW12_F 1 other
EGAD00001001738 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB38_M 1 other
EGAD00001001623 BBMRI - BIOS project - Freeze 1 - Bam files 2,117 bam,contig_fasta
EGAD00001001848 DDD DATAFREEZE 2014-11-04: 4293 trios - VCF files 12,539 vcf
EGAD00001001854 Exome sequencing of nine PCC/PGL tumors, SF and FFPE samples 18 bam
EGAD00001001658 Genome and transcriptome sequence data from an odontogenic ghost cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001968 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001969 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001307 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00010000872 Genotyped case and control sampes using HumanExome Beadchip 1,610
EGAD00001001791 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW15_F 1 other
EGAD00001001801 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW22_M 1 other
EGAD00001001706 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB22_C 1 other
EGAD00001001795 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW18_M 1 other
EGAD00001001748 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB43_C 1 other
EGAD00001001779 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB62_F 1 other
EGAD00001001739 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB40_C 1 other
EGAD00001001722 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB28_F 1 other
EGAD00001001766 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB55_C 1 other
EGAD00001001797 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW20_F 1 other
EGAD00001001828 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW47_M 1 other
EGAD00001001754 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB4_C 1 other
EGAD00001001833 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW4_F 1 other
EGAD00001001829 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW49_C 1 other
EGAD00001001838 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW51_C 1 other
EGAD00001001792 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW15_M 1 other
EGAD00001001762 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB51_M 1 other
EGAD00001001831 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW49_M 1 other
EGAD00001001807 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW27_M 1 other
EGAD00001001780 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB62_M 1 other
EGAD00001001718 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB27_C 1 other
EGAD00001001767 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB55_F 1 other
EGAD00001001781 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB8_C 1 other
EGAD00001001711 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB23_M 1 other
EGAD00001001823 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW46_C 1 other
EGAD00001001778 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB62_C 1 other
EGAD00001001819 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW38_M 1 other
EGAD00001001770 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB57_F 1 other
EGAD00001001743 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB41_F 1 other
EGAD00001001745 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB42_C 1 other
EGAD00001001842 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW52_F 1 other
EGAD00001001813 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW2_M 1 other
EGAD00001001725 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB30_F 1 other
EGAD00001001799 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW22_C 1 other
EGAD00001001835 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW50_C 1 other
EGAD00001001784 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW12_C 1 other
EGAD00001001818 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW38_F 1 other
EGAD00001001708 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB22_M 1 other
EGAD00001001750 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB43_M 1 other
EGAD00001001824 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW46_F 1 other
EGAD00001001830 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW49_F 1 other
EGAD00001001705 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB21_M 1 other
EGAD00001001793 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW18_C 1 other
EGAD00001001834 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW4_M 1 other
EGAD00001001789 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW14_M 1 other
EGAD00001001826 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW47_C 1 other
EGAD00001001768 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB55_M 1 other
EGAD00001001788 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW14_F 1 other
EGAD00001001803 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW24_F 1 other
EGAD00001001756 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB4_M 1 other
EGAD00001001775 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB60_C 1 other
EGAD00001001759 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB50_M 1 other
EGAD00001001721 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB28_C 1 other
EGAD00001001703 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB21_C 1 other
EGAD00001001776 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB60_F 1 other
EGAD00001001695 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB10_F 1 other
EGAD00001001805 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW27_C 1 other
EGAD00001001701 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB1_F 1 other
EGAD00001001796 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW20_C 1 other
EGAD00001001751 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB44_C 1 other
EGAD00001001804 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW24_M 1 other
EGAD00001001765 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB52_M 1 other
EGAD00001001744 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB41_M 1 other
EGAD00001001742 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB41_C 1 other
EGAD00001001816 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW32_M 1 other
EGAD00001001713 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB24_F 1 other
EGAD00001001700 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB1_C 1 other
EGAD00001001714 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB24_M 1 other
EGAD00001001815 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW32_F 1 other
EGAD00001001732 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB33_M 1 other
EGAD00001001699 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB15_M 1 other
EGAD00001001736 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB38_C 1 other
EGAD00001001825 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW46_M 1 other
EGAD00001001843 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW52_M 1 other
EGAD00001001753 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB44_M 1 other
EGAD00001001723 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB28_M 1 other
EGAD00001001741 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB40_M 1 other
EGAD00001001810 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW29_M 1 other
EGAD00001001839 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW51_F 1 other
EGAD00001001755 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB4_F 1 other
EGAD00001001760 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB51_C 1 other
EGAD00001001841 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW52_C 1 other
EGAD00001001822 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW3_M 1 other
EGAD00001001730 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB33_C 1 other
EGAD00001001786 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW12_M 1 other
EGAD00001001798 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW20_M 1 other
EGAD00001001716 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB25_F 1 other
EGAD00001001772 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB58_C 1 other
EGAD00001001717 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB25_M 1 other
EGAD00001001702 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB1_M 1 other
EGAD00001001719 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB27_F 1 other
EGAD00001001731 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB33_F 1 other
EGAD00001001712 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB24_C 1 other
EGAD00001001790 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW15_C 1 other
EGAD00001001758 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB50_F 1 other
EGAD00001001836 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW50_F 1 other
EGAD00001001764 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB52_F 1 other
EGAD00001001800 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW22_F 1 other
EGAD00001001794 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW18_F 1 other
EGAD00001001806 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW27_F 1 other
EGAD00001001697 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB15_C 1 other
EGAD00001001704 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB21_F 1 other
EGAD00001001809 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW29_F 1 other
EGAD00001001724 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB30_C 1 other
EGAD00001001817 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW38_C 1 other
EGAD00001001840 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW51_M 1 other
EGAD00001001727 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB31_C 1 other
EGAD00001001752 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB44_F 1 other
EGAD00001001783 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB8_M 1 other
EGAD00001001771 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB57_M 1 other
EGAD00001001726 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB30_M 1 other
EGAD00001001709 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB23_C 1 other
EGAD00001001811 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW2_C 1 other
EGAD00001001746 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB42_F 1 other
EGAD00001001820 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW3_C 1 other
EGAD00001001757 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB50_C 1 other
EGAD00001001715 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB25_C 1 other
EGAD00001001710 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB23_F 1 other
EGAD00001001761 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB51_F 1 other
EGAD00001001821 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW3_F 1 other
EGAD00001001694 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB10_C 1 other
EGAD00001001696 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB10_M 1 other
EGAD00001001707 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB22_F 1 other
EGAD00001001787 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW14_C 1 other
EGAD00001001814 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW32_C 1 other
EGAD00001001728 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB31_F 1 other
EGAD00001001747 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB42_M 1 other
EGAD00001001827 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW47_F 1 other
EGAD00001001733 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB35_C 1 other
EGAD00001001769 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB57_C 1 other
EGAD00001001763 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB52_C 1 other
EGAD00001001837 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW50_M 1 other
EGAD00001001802 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW24_C 1 other
EGAD00001001737 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB38_F 1 other
EGAD00001001749 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB43_F 1 other
EGAD00001001812 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW2_F 1 other
EGAD00001001698 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB15_F 1 other
EGAD00001001729 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB31_M 1 other
EGAD00001001773 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB58_F 1 other
EGAD00001001735 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB35_M 1 other
EGAD00001001720 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB27_M 1 other
EGAD00001001734 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB35_F 1 other
EGAD00001001774 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB58_M 1 other
EGAD00001001808 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW29_C 1 other
EGAD00001001740 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB40_F 1 other
EGAD00001001777 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB60_M 1 other
EGAD00010000871 CLL and normal B cell samples using 450K 226
EGAD00001001899 HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-driven Medulloblastoma 102 bam
EGAD00001001305 Dataset contains WES data from 3 astrocytoma patients: blood as control, primary tumor and recurrent tumor 9 bam
EGAD00001001987 March 2016 update of Whole genome bisulfite sequencing assay data (bams) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 18 bam
EGAD00001002683 A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases 22 bam
EGAD00001002255 Sequencing Data for DEEP Paper: "reChIP-seq reveals widespread bivalency of H3K4me3 and H3K27me3 in CD4+ memory T-Cells" Sample: 51_Hf01_BlCM_Ct (human, female, Blood, CD4+ central memory cell, normal control) Sequencing types are: total RNA, Whole Genome Bisulfite, ChipSeq (H3K27ac, H3K9me3, H3k36me3, H3K4me1, H3k27me3, H3K4me3, Input), reChipSeq (H3K27me3, H3K4me3) 1 readme_file,bam
EGAD00001001656 Genome and transcriptome sequence data from an atypical chronic lymphocytic leukemia patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002001 Mapped data (bam files) for high-throughput whole genome sequence data for 83 modern Aboriginal Australians 83 bam,bai
EGAD00001002016 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: LICA-FR. 12 bam,bai,readme_file
EGAD00001002014 Isolated populations have unique population genetics characteristics that can help boost power in genetic association studies for complex traits. Leveraging these advantageous characteristics requires an in-depth understanding of parameters that have shaped sequence variation in isolates. This study performs a comprehensive investigation of these parameters using low-depth whole genome sequencing (WGS) across multiple isolates. 6,840 sample_list,vcf
EGAD00001002011 RNA sequencing data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years. 64 bam
EGAD00001002032 Genome and transcriptome sequence data from an adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002012 ChIPseq data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years. 16 bam
EGAD00001002005 Using whole exome sequencing (WES), we identified homozygosity for a missense variant, VPS11: c.2536T>G (p.C846G), as the genetic cause of a leukoencephalopathy syndrome in two individuals from two unrelated Ashkenazi Jewish (AJ) families. Both patients exhibited highly concordant disease progression characterized by infantile onset leukoencephalopathy with brain white matter abnormalities, severe motor impairment, cortical blindness, intellectual disability, and seizures. 2 vcf
EGAD00001002043 Genome and transcriptome sequence data from a recurrent glioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002038 Genome and transcriptome sequence data from a peripheral T-cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 4 bam
EGAD00001002037 Genome and transcriptome sequence data from an adrenal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002036 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002022 Genome and transcriptome sequence data from a colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002017 Genome and transcriptome sequence data from a breast primary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002034 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002023 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002030 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002033 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002039 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002028 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002048 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002040 Genome and transcriptome sequence data from a squamous cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002031 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002020 Genome and transcriptome sequence data from a metastatic NPC patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002029 Genome and transcriptome sequence data from an ovarian granulosa patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002044 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002018 Genome and transcriptome sequence data from a melanoma skin cancer - squamous cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002047 Genome and transcriptome sequence data from a breast ductal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002045 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002042 Genome and transcriptome sequence data from an endometrial cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002049 Genome and transcriptome sequence data from an adrenal cortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002021 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002019 Genome and transcriptome sequence data from a patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002046 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002035 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002026 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 4 bam
EGAD00001002025 Genome and transcriptome sequence data from a colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002041 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002027 Genome and transcriptome sequence data from a colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002126 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PRAD-UK. 116 bam,bai,readme_file
EGAD00001002120 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: ORCA-IN. 26 readme_file,bai,bam
EGAD00001002123 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: MALY-DE. 202 readme_file,bai,bam
EGAD00001002121 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: BTCA-SG. 24 readme_file,bai,bam
EGAD00001002129 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: BRCA-EU. 158 readme_file,bai,bam
EGAD00001002154 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PAEN-AU. 98 readme_file,bai,bam
EGAD00001002155 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: LIRI-JP. 524 readme_file,bai,bam
EGAD00001002157 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: MELA-AU. 140 readme_file,bai,bam
EGAD00001002156 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: ESAD-UK. 198 readme_file,bai,bam
EGAD00001002132 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PACA-AU. 192 readme_file,bai,bam
EGAD00001002122 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: BRCA-UK. 90 readme_file,bai,bam
EGAD00001002119 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: LAML-KR. 18 readme_file,bai,bam
EGAD00001002130 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: CLLE-ES. 194 readme_file,bai,bam
EGAD00001002127 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PBCA-DE. 496 readme_file,bai,bam
EGAD00001002128 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PRAD-CA. 244 readme_file,bai,bam
EGAD00001002124 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: EOPC-DE. 113 readme_file,bai,bam
EGAD00001002153 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PAEN-IT. 74 bam,bai,readme_file
EGAD00001002125 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: BOCA-UK. 148 readme_file,bai,bam
EGAD00001002192 Additional sequencing data for 173 donors in EGAS00001000154, a study of Pancreatic Ductal Adenocarcinoma. WGS libraries were used for high-cellularity cases, WXS sequencing to high depth on low-cellularity cases. HiSeq 2xxx platform was used in all cases. The analysis files associated with this dataset are merged, de-duplicated bams aligned against GRCh37, one tumour and one normal bam per donor. 346 bam
EGAD00001002649 Variants called from RNA-seq data of meningioma tumors. 25 vcf
EGAD00001002247 The GoT2D study includes ~2800 samples, half T2D cases and half T2D controls, of Northern European ancestry sequenced over 3 three technologies: deep whole exome sequencing, low-pass (4x) whole genome sequencing, and OMNI 2.5M genotyping. Samples were ascertained to be phenotypically "extreme" (e.g. leaner, younger cases and older, more obese controls). Genotypes (SNVs, INDELs, and SVs) were called separately for each technology and then integrated via genotype refinement into a single phased reference panel; samples and variants were then excluded based on QC procedures described in Fuchsberger et al. Please note that 2 of the samples in the GoT2D vcf do not have phenotype data. 2,872 phenotype_file,vcf
EGAD00001002246 The T2D-GENES/GoT2D 13K exome sequencing study includes ~13,000 samples, half T2D cases and half T2D controls, from five ancestries (~5K Europeans, ~2K each of African-American, East-Asian, South-Asian, and Hispanic). Samples underwent deep exome sequencing, with SNVs and INDEls called according to GATK best practices; variant sites were then filtered according to the GATK best practices, and then samples and variants underwent further filtering based on aggregate genotype quality as described in Fuchsberger et al. (e.g. low call rate, excess heterozygosity for samples, low call rate or coverage for variants). Please note that one of the samples in the T2D-GENES vcf does not have phenotype data. 13,007 phenotype_file,vcf
EGAD00010000777 HipSci - Bardet-Biedl Syndrome - Genotyping Array - November 2014 0
EGAD00001002109 TSACP TruSeq Amplicon Panel dataset for the TraIT cell line use case 5 other,bam
EGAD00001002069 Complete genomics data for VCaP and PC346c. 2 other
EGAD00001002071 qDNAseq shallow sequencing dataset of the cell line use case. 5 other,bam
EGAD00001002115 Targeted sequencing of 173 genes in 2433 primary breast tumours. Data includes 2433 tumour samples, 523 adjacent normal (breast) samples and 127 blood samples. Libraries were prepared with Illumina's Nextera custom enrichment kit targetting all the exons of the most frequently mutated breast cancer genes. Libraries were multiplexed (48 libraries per lane) and sequenced on Illumina HiSeq 2000 (100bp paired-end reads). Somatic mutations were calling with a custom pipeline. We identified 40 mutation-driver (Mut-driver) genes, and determined associations between mutations, driver CNA profiles, clinical-pathological parameters and survival. We assessed the clonal states of Mut-driver mutations, and estimated levels of intra-tumour heterogeneity using mutant-allele fractions. The results emphasize the importance of genome-based stratification of breast cancer, and have important implications for designing therapeutic strategies. Referece: Pereira et al. (2016) The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nature Communications 3,083 bam,bai
EGAD00001002220 Enteropathy-associated T-cell lymphoma (EATL), a rare and aggressive intestinal malignancy of intraepithelial T lymphocytes, comprises two disease variants (EATL-I and EATL-II) differing in clinical characteristics and pathological features. Here we report findings derived from whole exome sequencing of 15 EATL-II tumor-normal tissue pairs. 15 vcf
EGAD00001001977 DDD DATAFREEZE 2014-11-04: 4293 trios - phenotypic and family descriptions 12,539 phenotype_file
EGAD00001002277 Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin 1 phenotype_file
EGAD00001002142 Paired PCR-free whole genome sequencing data of a matched metastatic melanoma cell line (COLO829) and normal across three lineages and across separate institutions, with independent library preparations, sequencing, and analysis. The data was generated with mean mapped coverages of 99X for COLO829 and 103X for the paired normal across three institutions. Overall, common events include >35,000 point mutations, 446 small insertion/deletions, and >6,000 genes affected by copy number changes. We present this reference to the community as an initial standard for enabling quantitative evaluation of somatic mutation pipelines across institutions. 24 bam,vcf,bai
EGAD00001001315 Phenotype determination by SNP-Typing using PCR and snapshotPCR with subsequent fragment analysis. We investigated 400 individuals from Northern Germany and detected up to 12 different SNPs to determine eye, hair and skin colour. More than 1000 different runs on a ABI3130 were performed This dataset includes: - Phenotype information for 400 samples - Summary and complete genotype calls for 12 SNPs on 400 samples. 399 phenotype_file
EGAD00001001382 TwinsUK whole exome sequencing using NimbleGen SeqCap EZ 248 bam,bai
EGAD00001001383 TwinsUK whole exome sequencing using NimbleGen 2.1M SeqCap 242 bam,bai
EGAD00001002265 A pulldown experiment with Agilent SureSelect probes designed on regions that were more likely to contain de novo mutations. 266 candidate sites were selected based on whole genome sequencing data. The probes also included the exons of genes that have been identified as neurodevelopmental disorder genes in DDD (the DDG2P genes) 1,336 targets. In addition, the design included the standard iPLEX sites. 4 bam,bai
EGAD00001002662 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: LINC-JP. 62 readme_file,bai,bam
EGAD00001002131 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: RECA-EU. 190 bam,bai,readme_file
EGAD00001002664 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: CMDI-UK. 98 readme_file,bai,bam
EGAD00001002278 58 vcf
EGAD00010000781 HipSci - Bardet-Biedl Syndrome - Methylation Array - April 2015 0
EGAD00010000817 HipSci - Monogenic Diabetes - Methylation Array - April 2015 0
EGAD00010000783 HipSci - Bardet-Biedl Syndrome - Expression Array - November 2014 0
EGAD00010000785 HipSci - Monogenic Diabetes - Expression Array - November 2014 0
EGAD00010000744 Subset 2 of osteoarthritis cases genotyped on Illumina 610k from the arcOGEN Consortium (http://www.arcogen.org.uk/) with consent for osteoarthritis studies only. 2,326
EGAD00010000742 Subset 1 of osteoarthritis cases genotyped on Illumina610k from the arcOGEN Consortium (http://www.arcogen.org.uk/) with broader consent. 5,383
EGAD00010000740 Osteoarthritis cases genotyped on Illumina HumanOmniExpress from the arcOGEN Consortium (http://www.arcogen.org.uk/) with broader consent. 674
EGAD00001002537 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002534 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002541 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002535 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002539 Genome and transcriptome sequence data from an oligodendroglioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002548 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002531 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002556 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002554 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002552 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002549 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002555 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002544 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002538 Genome and transcriptome sequence data from a uterine sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002545 Genome and transcriptome sequence data from a duodenal malignancy patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002540 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002547 Exome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002550 Genome and transcriptome sequence data from a primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001001655 Genome and transcriptome sequence data from an atypical teratoid rhabdoid tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002553 Genome and transcriptome sequence data from an unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002543 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002546 Genome and transcriptome sequence data from a melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002533 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002542 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002557 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002652 50 ng of genomic double stranded DNA was enzymatically sheared to an average size of 200 bp. Further processing was performed using Illumina Nextera Rapid Capture Custom Kit (Illumina) and 100 bp paired-end sequencing was performed with 24 samples per lane on a Illumina HiSeq 2000 (Illumina) to reach a coverage of 100-1000x. 284 bam,bai
EGAD00001002653 Genomic DNA from leukemic and remission bone marrow mononuclear cells was isolated with the QIAamp DNA Blood Extraction Kit (Qiagen, Venlo, The Netherlands). Libraries were prepared with the Illumina TruSeq DNA Sample Prep and TruSeq Exome Enrichment Kits (Illumina, San Diego, CA, USA) according to the manufacturer's recommendations. 100 bp paired-end sequencing was performed on a HiSeq 2000 (Illumina) to about 80x coverage. 57 bam,bai
EGAD00001001632 miRNA seq data of 13 cases (MMML) 13 bam
EGAD00001001619 miRNA seq data of 43 cases out of dataset EGAD00001000650 (MMML) 43 readme_file,bam
EGAD00001002665 Mapped sequence reads in BAM format for 64 individuals reporting Kanak ancestry recruited in New Caledonia sequenced at four times target coverage using the Illumina HiSeq 4000 platform. 64 bam,bai
EGAD00001002637 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002580 Genome and transcriptome sequence data from a right breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002609 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002604 Genome and transcriptome sequence data from a clear cell carcinoma of ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002568 Genome and transcriptome sequence data from a metastatic endometrial cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002639 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002628 Genome and transcriptome sequence data from a squamous cell carcinoma of anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002579 Genome and transcriptome sequence data from a carcinoma of left lower outer quadrant patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002636 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002622 Genome and transcriptome sequence data from a metastatic colorectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002623 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002559 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002558 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002575 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002648 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002611 Genome and transcriptome sequence data from an adenocarcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002573 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002598 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001001876 Genome and transcriptome sequence data from a colorectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study. These data are included in the manuscript entitled, "Response to Angiotensin Blockade with Irbesartan in a Patient with Metastatic Colorectal Cancer". 4
EGAD00001002621 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002647 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002638 Genome and transcriptome sequence data from a metastatic prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002642 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002584 Genome and transcriptome sequence data from a vulvar metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002593 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002592 Genome and transcriptome sequence data from a pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002588 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002617 Genome and transcriptome sequence data from a small cell/neuroendocrine carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002631 Genome and transcriptome sequence data from a serous endometrial cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002630 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002601 Genome and transcriptome sequence data from an invasive ductal carcinoma of left breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001001961 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 4
EGAD00001002606 Genome and transcriptome sequence data from an adenocarcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002589 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002577 Genome and transcriptome sequence data from an adenocarcinoma of primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002565 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 5 bam
EGAD00001002603 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002576 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002627 Genome and transcriptome sequence data from an adenoid cystic carcinoma of the trachea patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002620 Genome and transcriptome sequence data from a myxoid liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002567 Genome and transcriptome sequence data from a rectosigmoid adenocarcinoma (colorectal cancer) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002645 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002632 Genome and transcriptome sequence data from a testicular cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002634 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002582 Genome and transcriptome sequence data from a squamous cell carcinoma of anal canal patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002600 Genome and transcriptome sequence data from an adnexal tumor probable of Wolffian origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002560 Genome and transcriptome sequence data from a cervical cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002610 Genome and transcriptome sequence data from an invasive carcinoma of left breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002570 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002561 Genome and transcriptome sequence data from a metastatic cervical cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002646 Genome and transcriptome sequence data from an epithelioid mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002599 Genome and transcriptome sequence data from a medullary thyroid carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002641 Genome and transcriptome sequence data from a metastatic small cell carcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002586 Genome and transcriptome sequence data from a squamous cell carcinoma of vulva patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002583 Genome and transcriptome sequence data from a retroperitoneal leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002607 Genome and transcriptome sequence data from a pancreatic cancer (likely PNET) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002635 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002590 Genome and transcriptome sequence data from an adenomacarcinoma of vulva patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002625 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002587 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002572 Genome and transcriptome sequence data from an infiltrating ductal carcinoma of right breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002619 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002564 Genome and transcriptome sequence data from an adenocarcinoma of lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002571 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002614 Genome and transcriptome sequence data from a thymic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002640 Genome and transcriptome sequence data from a clival chordoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002643 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002574 Genome and transcriptome sequence data from a ductal carcinoma of left breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002615 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002585 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002581 Genome and transcriptome sequence data from a metastatic myxofibrosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002633 Genome and transcriptome sequence data from an endometrial carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002612 Genome and transcriptome sequence data from an esophageal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002644 Genome and transcriptome sequence data from a multifocal hepatocellular carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002608 Genome and transcriptome sequence data from a pleomorphic spindle cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001001962 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002597 Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002596 Genome and transcriptome sequence data from a porocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002605 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002566 Genome and transcriptome sequence data from a uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002594 Genome and transcriptome sequence data from a peritoneal mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002591 Genome and transcriptome sequence data from a neuroendocrine tumor likely pancreatic origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002624 Genome and transcriptome sequence data from a squamous cell carcinoma of unknown primary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002618 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002616 Genome and transcriptome sequence data from a superficial pleomorphic liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002578 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002629 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002626 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002595 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the GE junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002569 Genome and transcriptome sequence data from a primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002602 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002536 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002613 Genome and transcriptome sequence data from a breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001001965 Genome and transcriptome sequence data from a lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001963 Genome and transcriptome sequence data from a non small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002562 Genome and transcriptome sequence data from an osteogenic sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002563 Genome and transcriptome sequence data from a follicular lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2 bam
EGAD00001002532 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001002551 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001001966 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002729 Haplotype Reference Consortium Release 1.1 - subset for release via the EGA 11,227 other,vcf,readme_file,tabix,vcf_aggregate
EGAD00001002739 Aligned sequence data from 14 Prostate cancer samples with BRCA2 mutations 49 bam
EGAD00001001311 Genome and transcriptome sequence data from a peritoneal mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3 bam
EGAD00001000723 Relative Spatial Homogeneity of Embryonal Brain Tumors of Childhood 42 bam
EGAD00001002771 Modified alignments based on a single sample, each with different characteristics 61 bam
EGAD00001002684 Whole genome sequencing of 98 tumour-normal pairs for the PAEN-AU pancreatic neuroendocrine cancer project. 196 bam
EGAD00001002743 These samples comprise both melanoma cases and controls sequenced for a selection of loci linked to disease susceptibility. These bams are a subset of the sequencing restricted specifically to the GRCh37 coding areas of the BAP1 gene. 3,186 bam
EGAD00001003234 Aligned whole genome sequence from AML relapse project 33
EGAD00001003300 Paired-end reads were aligned to human reference genome build hg19 by BWA. Single nucleotide variants and small insertions/deletions were called by GATK resulting in a single VCF file including all 176 samples. 175
EGAD00001003298 BAM outputs from RSEM (https://deweylab.github.io/RSEM/) analysis of RNASeq sequencing on HiSeq platform of tumour samples from 95 pancreatic adenocarcinoma cases. 96
EGAD00001002748 DDD DATAFREEZE 2014-11-04: 4293 trios - exome sequence CRAM files 12,548 cram,bam
EGAD00001003101 The need for a detailed catalogue of local variability for the study of rare diseases within the context of the Medical Genome Project motivated the whole exome sequencing of 267 unrelated individuals, representative of the healthy Spanish population. 267 vcf
EGAD00001003791 The SAHGP characterises the genomes of 24 individuals (8 Coloured and 16 black southeastern Bantu-speakers) using deep whole genome sequencing (WGS). 3
EGAD00001002898 Oliocapture sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are sequencing libraries from the extension cohort of 277 patients. Specifically, there are 402 tumor libraries and 82 normal libraries. 484
EGAD00010001141 Summary data from Meta-analysis of Genome-Wide-Association Studies for plasma levels of Coagulation Factor XI (FXI) 0
EGAD00001002897 Whole genome sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are libraries from 41 patients. Specifically: 15 transformed follicular lymphoma (TFL), 6 early progressers (PFL), and 20 non-early progressers (NPFL). For TFL and PFL patients, trios consisting of diagnostic (T1), transformed/progressed (T2) and a matching normal are available (n = 63 libaries in total). For NPFL patients, a tumor-normal pair are available (n = 40 libraries). 103
EGAD00001001308 Genome and transcriptome sequence data from a primary unknown cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001001309 Genome and transcriptome sequence data from an appendix cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00010001029 Summary statistics for a multi-cohort epigenome-wide association study. This includes summary statistics (effect-size, standard error, p-value) for 470,000 methylation markers. 0
EGAD00001003073 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the pancreas patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003078 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003006 Genome and transcriptome sequence data from a metastatic medullary thyroid cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002993 Genome and transcriptome sequence data from a metastatic carcinoma of primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003003 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002983 Genome and transcriptome sequence data from a metastatic carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003023 Genome and transcriptome sequence data from a metastatic renal cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003046 Genome and transcriptome sequence data from a sigmoid cancer and an ampullary cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003070 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002977 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003048 Genome and transcriptome sequence data from a metastatic pancreatic neuroendocrine tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002974 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003081 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003077 Genome and transcriptome sequence data from a metastatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003024 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003075 Genome and transcriptome sequence data from a metastatic colon caner patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003065 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma of the palate patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003029 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003051 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002984 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002976 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003063 Genome and transcriptome sequence data from an atypical bronchial carcinoid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003058 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003031 Genome and transcriptome sequence data from a metastatic collecting duct kidney cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003016 Genome and transcriptome sequence data from a metastatic ductal carcinoma of the breast patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003087 Genome and transcriptome sequence data from a pancreatic neuroendocrine cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003037 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003035 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003012 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003066 Genome and transcriptome sequence data from an appendiceal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003076 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003088 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002986 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002999 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003042 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002991 Genome and transcriptome sequence data from a cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003014 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002981 Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003002 Genome and transcriptome sequence data from a metastatic adult granulosa cell tumour patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002990 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003090 Genome and transcriptome sequence data from a metastatic leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003054 Genome and transcriptome sequence data from a low-grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003022 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003000 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003044 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003028 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003013 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003062 Genome and transcriptome sequence data from an extraosseous osteosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002996 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003011 Genome and transcriptome sequence data from a squamous cell carcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003005 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003001 Genome and transcriptome sequence data from a serous carcinoma of fallopian tube patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003071 Genome and transcriptome sequence data from a pleural mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003045 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003082 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003033 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003015 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003009 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003060 Genome and transcriptome sequence data from a liposarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003019 Genome and transcriptome sequence data from a metastatic uveal melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002979 Genome and transcriptome sequence data from a GI primary (prev breast cancer) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003007 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003026 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003059 Genome and transcriptome sequence data from a metastatic mullerian tumor of endometrium patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002980 Genome and transcriptome sequence data from a metastatic fibrolamellar hepatocelluar carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003010 Genome and transcriptome sequence data from a metastatic uterine leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003083 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002988 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003080 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003008 Genome and transcriptome sequence data from a metastatic adenocarcinoma presumably of ovarian origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003021 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003049 Genome and transcriptome sequence data from a prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002972 Genome and transcriptome sequence data from a breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003025 Genome and transcriptome sequence data from an endometrial adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003020 Genome and transcriptome sequence data from a low grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003056 Genome and transcriptome sequence data from a solitary fibrous tumors (sarcoma) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002997 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003040 Genome and transcriptome sequence data from a chordoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003055 Genome and transcriptome sequence data from a small bowel carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003047 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003036 Genome and transcriptome sequence data from an ovarian adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003030 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002975 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma of unknown primary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003039 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002982 Genome and transcriptome sequence data from a metastatic rectosigmoid adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003091 Genome and transcriptome sequence data from a clear cell carcinoma of ovary patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002987 Genome and transcriptome sequence data from a metastatic endocervical adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003064 Genome and transcriptome sequence data from an ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002998 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003137 Metastatic and primary tumour samples were collected from 4 patients with advanced breast cancer. Samples were collected at autopsy and also from biopsies taken during life. Tumour and germline samples are available. Whole exome sequencing was performed on all samples. 52
EGAD00001003041 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003017 Genome and transcriptome sequence data from a metastatic large cell neuroendocrine tumour of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003068 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002985 Genome and transcriptome sequence data from a adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003067 Genome and transcriptome sequence data from a metastatic gastroesophageal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002995 Genome and transcriptome sequence data from a carcinosarcoma of the uterus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003079 Genome and transcriptome sequence data from a presumed metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003069 Genome and transcriptome sequence data from a pancreatic neuroendocrine tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003052 Genome and transcriptome sequence data from a metastatic malignant peripheral nerve sheath tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003018 Genome and transcriptome sequence data from a metastatic clear cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003085 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002891 Genome and transcriptome sequence data from a leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003084 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003032 Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003053 Genome and transcriptome sequence data from an adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003072 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003061 Genome and transcriptome sequence data from an adenocarcinoma of the distal esophagus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002978 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003043 Genome and transcriptome sequence data from a breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003038 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003089 Genome and transcriptome sequence data from a pancreatic neuroendocrine patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003004 Genome and transcriptome sequence data from a glioblastoma multiforme patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003050 Genome and transcriptome sequence data from a serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003141 List of SNPs, and their frequencies, extracted from a low pass whole genome sequencing of 3,514 individuals. 1
EGAD00001001967 Genome and transcriptome sequence data from an adenocarcinoma of right lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001657 Genome and transcriptome sequence data from a parotid gland cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001002973 Genome and transcriptome sequence data from a rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002992 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001964 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003132 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: GACA-CN. 84
EGAD00010001184 This data set includes the following summary level data file used for the imputation data: imputation.sv.assoc.txt: results from single variant association analysis in imputed samples 0
EGAD00010001185 This data set includes the following summary level data files used for the GoT2D WGS analysis: wgs.assoc.samples.list: list of samples to keep for association analysis wgs.assoc.variants.list: list of variants to keep for association analysis wgs.sv.assoc.txt: single variant association results 0
EGAD00010001188 This data set includes the following summary level data files used for the 13k analysis of T2D-GENES data: wes.variants.list: list of variants to keep for any analysis of the exomes data wes.assoc.samples.list: list of samples to keep for association analysis wes.assoc.variants.list: list of variants to keep for association analysis wes.sv.assoc.txt: single variant association analysis results wes.gene.ptv.variants.list.txt: list of protein truncating variants to use in gene-level analysis wes.gene.ptv.assoc.txt: results from gene-level tests of protein truncating variants wes.gene.nsstrict.variants.list.txt: list of NSstrict variants to use in gene-level analysis wes.gene.nsstrict.assoc.txt: results from gene-level tests of NSstrict variants wes.gene.nsbroad.variants.list.txt: list of NSbroad variants to use in gene-level analysis wes.gene.nsbroad.assoc.txt: results from gene-level tests of NSbroad variants wes.gene.ns.variants.list.txt: list of non synonymous variants to use in gene-level analysis wes.gene.ns.assoc.txt: results from gene-level tests of non synonymous variants 0
EGAD00010001187 This data set includes the following summary level data file used for the exome chip analysis: exome_chip.sv.assoc.txt: results from single variant association analysis in exome chip 0
EGAD00001003118 Targeted capture sequencing for cases with MDS who were subjected to unrelated bone marrow transplantation via Japan marrow donor program 797
EGAD00001003164 Variant call set (vcf) for three (primary and two recurrent) tumors 3
EGAD00001003139 Aligned sequence data for 124 CPCGene Tumour/Normal Pairs from the 200PG Study 262
EGAD00001003086 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003057 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003034 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002994 Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001002989 Genome and transcriptome sequence data from a medullary thyroid cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003074 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001001467 WGS of 8 trios - affected child and both normal parents 24
EGAD00001003027 Genome and transcriptome sequence data from an anaplastic myxopapillary ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003220 Whole genome, whole exome, and custom panel sequencing of high-grade meningioma cohort 188
EGAD00001003162 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: PACA-CA. 298
EGAD00010001211 Inverse variance weighted fixed effect meta-analysis of three European GWAS studies of the offspring of Pre-eclampsia affected births (2658 Cases and 308267 Controls). 4
EGAD00001003318 RNA-sequencing alignment for SYSCOL colorectal adenoma-carcinoma samples 314
EGAD00001003263 ICGC DCC Release 24, PACA-CA Deep KRAS sequencing 82
EGAD00001003227 ICGC PCAWG Dataset for WGS BAM aligned using BWA MEM. Project: OV-AU. 146
EGAD00001003270 ICGC DCC Release 24, PACA-CA Whole Genome sequence merged alignments 95
EGAD00001003260 The cell lines in this study are a combination of internally sequenced (cosmic) and externally sequenced cell lines known to be “double-wild-type” (lacking BRAF and NRAS somatic mutations). These sequences were realigned in this data set for consistency. 22
EGAD00001003264 ICGC DCC Release 24, PACA-CA Exome sequence 190
EGAD00001003295 Integrated callset of high coverage Egyptian genomes from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j.ajhg.2015.04.019) 3
EGAD00001003294 Integrated callset of high coverage Ethiopian genomes from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j.ajhg.2015.04.019) 5
EGAD00001003297 9
EGAD00001003591 Merged bam files for PACA-CA Whole Genome Sequencing, for DCC release 25 211
EGAD00001003301 Whole exome sequencing of 10 metastatic biopsies from four TRACERx100 patients (see EGA dataset EGAS00001002247), collected either after relapse or death. The data from these samples are initially published with Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature, http://dx.doi.org/10.1038/nature22364 (2017). Abstract: Earlier detection of relapse following primary surgery for non-small cell lung cancer and the characterization of emerging subclones seeding metastatic sites might offer new therapeutic approaches to limit tumor recurrence. The potential to non-invasively track tumor evolutionary dynamics in ctDNA of early-stage lung cancer is not established. Here we conduct a patient-specific approach to ctDNA profiling in the first 100 lung TRACERx (TRAcking Cancer Evolution through therapy (Rx)) study participants, including one patient co-recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release in early-stage non-small cell lung cancer and perform tumor volume limit of detection analyses. Through blinded profiling of post-operative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients destined to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastases, providing a new approach for ctDNA driven therapeutic studies. 10
EGAD00001003296 Integrated callset of low coverage Ethiopian and Egyptian genomes from the Pagani et al. 2015 AJHG paper (doi: http://dx.doi.org/10.1016/j.ajhg.2015.04.019) 220
EGAD00001003206 BACKGROUND TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). METHODS Multiregion high-depth whole-exome sequencing (M-seq) was performed on 100 early stage NSCLC tumors resected prior to systemic therapy. A total of 327 tumor regions were sequenced and analyzed to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between ITH and recurrence-free survival (RFS). RESULTS Widespread ITH was observed for both somatic copy number alterations (median 48% [0.03-88%]) and mutations (median 30% [0.5-93%]). Driver mutations in EGFR, MET, BRAF and TP53 were almost always clonal. However, heterogeneous driver alterations occurring later in evolution were found in over 75% of tumors and were common in PIK3CA, NF1 and genes involved in chromatin modification and DNA response and repair. Genome doubling and ongoing dynamic chromosomal instability (CIN), illustrated by mirrored subclonal allelic imbalance, were identified as causes of ITH resulting in parallel evolution of driver copy number events, including amplifications of CDK4, FOXA1, and BCL11A. Elevated copy number heterogeneity was associated with shorter RFS (HR=4.9, P=0.00044), which remained significant in a multivariate analysis. CONCLUSIONS ITH mediated through CIN, rather than point mutational heterogeneity, was associated with increased risk of relapse, supporting its value as a prognostic predictor, and the need to target this high-risk phenotype. 427
EGAD00001003328 Clinical and genetic information of an individual with RVOT-VT and a KCNK2 (TREK1) gene mutation obtained after whole exome sequencing. 1
EGAD00001003303 The evolution of four breast cancers was analyzed using longitudinal samples collected over 2-15 years. Whole-genome sequencing and single-cell RNA-Seq were used to analyze evolution. We have deposited VCF files for SNV, indel, and structural variant calls from WGS data, and a text file showing transcripts per million (TPM) expression for the single-cell RNA-Seq data. 16
EGAD00001003353 BAM outputs from STAR (https://github.com/alexdobin/STAR) analysis of RNASeq sequencing on HiSeq platform of 56 tumour samples from 46 melanoma cases. Gene model = Ensembl version 70 56
EGAD00001003357 Aligned, merged and deduplicated BAM files from HiSeq whole exome sequencing of 106 samples: matched tumour-normal pairs from 53 melanoma patients. 106
EGAD00001003388 Aligned, merged and deduplicated BAM files from HiSeq whole genome sequencing of 366 samples: matched tumour-normal pairs from 183 melanoma patients. 366
EGAD00001003360 Bam files containing mitochondrial alignments, extracted from CPCGene Whole Genome Alignments 432
EGAD00001003361 VCF files containing mitochondrial variant calls using MToolbox 432
EGAD00001003127 WGS data of medulloblastoma tumor/control pairs. 482
EGAD00001003126 WGS data of medulloblastoma tumor/control pairs. 74
EGAD00001003128 Exome sequencing data for medulloblastoma tumor/control pairs 35
EGAD00001003421 Sequence data of 28 Samples (19 chronic lymphocytic leukemia, 9 control) Including RNA-Seq and ChIP-Seq of following histone modifications: H3, H3K4me1, H3K4me3, H3K9ac, H3K9me3, H3K27ac, H3K27me3, H3K36me3 Project see: http://www.cancerepisys.org/ 28
EGAD00001001943 Here, we studied well-phenotyped individuals from the Flemish Gut Flora Project (FGFP, N=1,106, Belgium) and the effect of environments on microbiome. The 69 major significant phenotypes found in this study are provided. 1,106
EGAD00001002890 Exome sequencing of 96 French-Canadians 102
EGAD00001003221 Aligned, merged and deduplicated BAM files from BGISeq-500 sequencing of six samples: matched tumour-normal pairs from three melanoma patients. 6
EGAD00001003222 Aligned, merged and deduplicated BAM files from HiSeqXTen sequencing of six samples: matched tumour-normal pairs from three melanoma patients. 6
EGAD00001003455 The MHC vcf call set was generated using a modified AsmVar and BayesTyper pipeline. In contrast to the original pipeline, where variant calling is performed using alignment of collapsed assemblies to a reference genome, the MHC call set was produced using alignment of phased MHC haplotypes. Two iterations of BayesTyper was run, a first iteration for each haplotype seperately and a second iteration performing joint variant calling on all haplotypes. The sample IDs for the fathers and mothers are TrioID-01 and TrioID-02, respectively, and the IDs for the children are TrioID-0x, where x is a number between 3 and 7. 25
EGAD00001003188 Variants and genotypes called in 50 danish parent-offspring trios from 80x Illumina sequencing data using BayesTyper. Data was produced using different insert size libraries of the sizes 180, 500, 800, 2000, 5000, 10000 and 20000 bp. The sample IDs for the fathers and mothers are TrioID-01 and TrioID-02, respectively, and the IDs for the children are TrioID-0x, where x is a number between 3 and 7 150
EGAD00001003186 Variants on the Y chromosome for 62 danish males in VCF format from the GenomeDenmark Phase 2 cohort. Variants were called using reference based approaches such as the haplotype-caller module from GATK and using alignment of denovo assemblies to the reference using ASMvar. 68
EGAD00001003157 Alignment of Genome Denmark Phase II dataset to GRCh38. The dataset consists of 150 Danish individuals (50 trios) sequenced to 80X. The BAM-file contains data from multiple libraries created from one individual with libraries of 180, 500, 800, 2000, 5000, 10000 and 20000 bp. The libraries were created using standard Illumina protocols for paired end reads (180-800bp libraries) and mate pair libraries (2kb-20kb). 150
EGAD00001003125 WGS data of medulloblastoma tumor/control pairs. 224
EGAD00001003586 Whole Genomes Define Concordance in Matched Primary, Xenograft, and Organoid Models of Pancreas Cancer - WGS mapped reads 54
EGAD00001003783 Recent studies using next-generation sequencing strategies have described the landscape of genetic alterations in diffuse large B-cell lymphoma (DLBCL). However, little is known about the clinical relevance of recurrent mutations and copy number alterations and their transcriptional footprints. This study examines the frequency, interaction and clinical impact of recurrent genetic aberrations in DLBCL using high-resolution technologies in a large population-based cohort. 324
EGAD00001003509 Whole Exome Sequencing reads consisting of BAM paired end reads from Follicular Lymphoma samples. 11
EGAD00001003463 These are the vcf files of exome sequencing of the two probands who were found to harbor mutations in KLB. Sample: EGAN00001564799 is the proband 1; Sample: EGAN00001564800 is the proband 11 in the KLB paper. Exome capture was performed using the SureSelect All Exon capture (Agilent Technologies, Santa Clara, CA USA) and sequenced on the HiSeq2500 (Illumina, San Diego CA USA). 2
EGAD00001003753 single nucleotide variant calls from somatic sniper, vcf format. input for subclonal reconstruction 20
EGAD00001003754 structural variant calls from Delly, vcf format 37
EGAD00001003752 single nucleotide variant calls from somatic sniper, vcf format 34
EGAD00001003560 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: MALY-DE. 99
EGAD00001003548 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: CLLE-ES. 74
EGAD00001003592 Merged bam files for PACA-CA Whole Exome Sequencing, for DCC release 25 216
EGAD00001003282 Analysis scripts and output 37
EGAD00001003247 Liberal variant calls generated with VarScan 37
EGAD00001003203 Aligned (hg19) sequencing data from 16 participants with FL/DLBCL. 37
EGAD00001003561 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: MALY-DE. 99
EGAD00001003547 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: LIRI-JP. 130
EGAD00001003559 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: RECA-EU. 100
EGAD00001003558 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: RECA-EU. 100
EGAD00001003549 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: CLLE-ES. 74
EGAD00001003410 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: PACA-AU. 81
EGAD00001003415 ICGC PCAWG Dataset for RNA-Seq BAM aligned using Star. Project: OV-AU. 93
EGAD00001003416 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: OV-AU. 93
EGAD00001003411 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: PACA-AU. 81
EGAD00001001337 We propose to definitively characterise the somatic genetics of breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses. 607
EGAD00001003584 Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - RNA-Seq mapped reads 50
EGAD00001003585 Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - WGS mapped reads 106
EGAD00001003589 Ultra-Fast Patient-Derived Xenografts Identify Functional and Spatial Tumour Heterogeneities that Drive Therapeutic Resistance - WXS mapped reads 27
EGAD00001003546 ICGC PCAWG Dataset for RNA-Seq BAM aligned using TopHat2. Project: LIRI-JP. 130
EGAD00001003583 516 DNA samples were collected from individuals upon enrollment into the European Prospective Investigation into Cancer and Nutrition study between 1993 and 1998 across 17 different centers. 126bp pair-end reads sequencing data from the Illumina platform were converted to fastq format, the 2bp molecular barcode information at each read of the pair was trimmed and was written in the reads name. The Thymine nucleotide required for ligation was removed from the sequences. Burroughs-Wheeler Aligner (BWA-mem) was used for alignment of the processed fastq files to the reference hg19 genome, following indel-re-alignment using GATK. An in-house algorithm was written to collapse read families that share the same molecular barcode sequence 516
EGAD00001003744 Genome and transcriptome sequence data from a pleomorphic xanthoastrocytoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003712 Genome and transcriptome sequence data from a primary of unknown origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003668 Genome and transcriptome sequence data from a metastatic rhabdomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003680 Genome and transcriptome sequence data from a low grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003666 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003709 Genome and transcriptome sequence data from a high-grade serous fallopian tube carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003612 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003737 Genome and transcriptome sequence data from a sinus adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003724 Genome and transcriptome sequence data from a T-cell rich B cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003683 Genome and transcriptome sequence data from a metastatic high grade sarcomatous neoplasm nos patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003667 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003635 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003628 Genome and transcriptome sequence data from a metastatic adenocarcinoma of appendiceal origin patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003674 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003624 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003645 Genome and transcriptome sequence data from an anaplastic ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003639 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003643 Genome and transcriptome sequence data from a metastatic cecal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003718 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003739 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003650 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003653 Genome and transcriptome sequence data from a non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003630 Genome and transcriptome sequence data from a radiation-induced pleomorphic sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003670 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003615 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003713 Genome and transcriptome sequence data from a low-grade serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003671 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 3
EGAD00001003655 Genome and transcriptome sequence data from a metastatic colon cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003672 Genome and transcriptome sequence data from a metastatic clear cell ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003690 Transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 1
EGAD00001003686 Genome and transcriptome sequence data from a metastatic neuroendocrine tumor arising from small bowel patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003743 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003682 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003687 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003660 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003642 Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003616 Genome and transcriptome sequence data from an adenocarcimona of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003652 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003734 Genome and transcriptome sequence data from a spindle cell carcinoma of the left parotid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003725 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectosigmoid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003647 Genome and transcriptome sequence data from an anal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003604 Genome and transcriptome sequence data from a metastatic gallbladder cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003619 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003685 Genome and transcriptome sequence data from an osterosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003692 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumour patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003684 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003658 Genome and transcriptome sequence data from a primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003736 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003679 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003700 Genome and transcriptome sequence data from a thymic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003694 Genome and transcriptome sequence data from a pleomorphic sarcomatoid epithelioid carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003608 Genome and transcriptome sequence data from a metastatic small cell carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003730 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003664 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003699 Genome and transcriptome sequence data from a metastatic lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003625 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003675 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003741 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003733 Genome and transcriptome sequence data from a metastatic uterine leiomyosarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003631 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003614 Genome and transcriptome sequence data from a metastatic non-small cell lung carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003665 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003623 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003716 Genome and transcriptome sequence data from a melanoma of the right buccal mucosa patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003702 Genome and transcriptome sequence data from a high grade serous carcinoma of the fallopian tube/ovary/peritoneum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003657 Genome and transcriptome sequence data from an adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003726 Genome and transcriptome sequence data from a large-cell neuroendocrine lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003609 Genome and transcriptome sequence data from a metastatic serous ovarian cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003610 Genome and transcriptome sequence data from a mullerian mixed tumor with carcinosarcoma of the ovaries patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003696 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003640 Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003606 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003731 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003656 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003723 Genome and transcriptome sequence data from a squamous cell carcinoma of the anus patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003717 Genome and transcriptome sequence data from a metastatic non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003710 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003662 Genome and transcriptome sequence data from a left cavernous sinus invasive skull meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003641 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003708 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003673 Genome and transcriptome sequence data from a metastatic adenocarcinoma of the ge junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003644 Genome and transcriptome sequence data from a metastatic spindle cell sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003632 Genome and transcriptome sequence data from a chronic lymphocytic leukemia patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003728 Genome and transcriptome sequence data from a metastatic gastrointestinal stromal tumor patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003693 Genome and transcriptome sequence data from a metastatic rectal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003721 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003621 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003629 Genome and transcriptome sequence data from a metastatic gastric cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003638 Genome and transcriptome sequence data from a metastatic prostate cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003626 Genome and transcriptome sequence data from a retroperitoneal mucinous cystic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003636 Genome and transcriptome sequence data from a metastatic paraganglioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003732 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003678 Genome and transcriptome sequence data from a thymoma carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003698 Genome and transcriptome sequence data from a locally advanced right breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003681 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003714 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003659 Genome and transcriptome sequence data from an ependymoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003715 Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003729 Genome and transcriptome sequence data from a peripheral T-cell lymphoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003742 Genome and transcriptome sequence data from an adenocarcinoma of the lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003648 Genome and transcriptome sequence data from a glioblastoma multiforme patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003613 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003637 Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003720 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003620 Genome and transcriptome sequence data from a metastatic colorectal carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003688 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003607 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003695 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003605 Genome and transcriptome sequence data from a metastatic colonic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003719 Genome and transcriptome sequence data from a metastatic breast carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003617 Genome and transcriptome sequence data from a non-small cell lung cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003646 Genome and transcriptome sequence data from a squamous cell carcinoma of ge junction patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003633 Genome and transcriptome sequence data from a metastatic rectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003722 Genome and transcriptome sequence data from a primary unknown patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003738 Genome and transcriptome sequence data from a Ewing sarcoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003627 Genome and transcriptome sequence data from a salivary duct carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003740 Genome and transcriptome sequence data from a metastatic pancreatic cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003677 Genome and transcriptome sequence data from a metastatic colorectal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003701 Genome and transcriptome sequence data from a metastatic myoepithelial carcinoma of parotid patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003611 Genome and transcriptome sequence data from a metastatic cecal cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003651 Genome and transcriptome sequence data from a metastatic colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003669 Genome and transcriptome sequence data from a metastatic mucinous adenocarcinoma of the rectum patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003622 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003711 Genome and transcriptome sequence data from a bilateral breast lobular cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003697 Genome and transcriptome sequence data from a metastatic meningioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003649 Genome and transcriptome sequence data from a metastatic colon adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003663 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003676 Genome and transcriptome sequence data from a metastatic adrenocortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003735 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003634 Genome and transcriptome sequence data from a solitary fibrous tumors (sarcoma) patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003654 Genome and transcriptome sequence data from a metastatic breast cancer patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003603 Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003661 Genome and transcriptome sequence data from an advanced adenocarcinoma of lung patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003689 Genome and transcriptome sequence data from a metastatic epitheloid angiomyelolipoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003727 Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003691 Genome sequence data from a metastatic squamous cell carcinoma of the oropharynx patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003618 Genome and transcriptome sequence data from a mesothelioma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study 2
EGAD00001003210 Whole genome sequencing data for MMML (cell_line) 8
EGAD00001003207 Whole genome sequencing data for MMML (28 tumor/control pairs) 56
EGAD00001003283 Whole genome sequencing data for MMML (healthy cell_line) 24
EGAD00001003285 RNA sequencing data for MMML (3 tumor samples and 1 gcbcell) 5
EGAD00001003286 Whole genome sequencing data for MMML (7 tumors and 8 controls) 15
EGAD00001003274 Whole genome sequencing data for MMML (tumor/control pairs and one cell_line) 315
EGAD00001003795 This dataset includes Nimblegen SeqCap EZ Exome v3 data for each lesion of three patients with multicentric glioma. For two patients, each lesion was sequenced along with whole blood. For a third patient, 3 pieces from the right lesion and 4 pieces from the left were sequenced along with whole blood. In each case BAM files that have been aligned with BWA mem alignment are available. 15
EGAD00010000230 WTCCC2 samples from Hypertension Cohort - Illuminus 2,943
EGAD00010000232 WTCCC2 samples from Type 2 Diabetes Cohort - Illuminus 2,975
EGAD00010000236 WTCCC2 samples from Coronary Artery Disease Cohort - Illuminus, GenoSNP 3,125
EGAD00010000385 MRCA sample using 300K Illumina 300K - GenomeStudio 394
EGAD00010000150 WTCCC2 project samples from Ankylosing spondylitis Cohort Illumina_670k - Illuminus 2,005
EGAD00001000150 Targeted re-sequencing of 97 genes in T-ALL 454 GS FLX Titanium 33 sff
EGAD00001000224 Enrichment of CRC 454 GS FLX Titanium; 2 bam
EGAD00001000225 Deep sequencing of KRAS 454 GS FLX Titanium; 8 fastq
EGAD00001000708 AZIN1 amplicon sequencing data of the EGAS00001000495 project. 454 GS FLX Titanium; 69 fastq
EGAD00001000272 Genomic Alterations in Gingivo-buccal Cancer: ICGC-India Project_YR01 454 GS FLX Titanium;, Illumina HiSeq 2000; 200 bam
EGAD00001000220 Deep sequencing of CTCs 454 GS FLX Titanium;, Illumina MiSeq; 3 bam
EGAD00001003454 Validation of HLA variation of 8 individuals from the GenomeDenmark Phase 2 study. Validation is performed Sanger sequencing of selected amplicons (5-10 amplicons per sample). AB 3730xL Genetic Analyzer;CAPILLARY 8
EGAD00001000888 NSCLC WGS. AB 5500 Genetic Analyzer; 4 bam
EGAD00001001436 AB 5500 Genetic Analyzer; 4 bam
EGAD00001003385 Whole-exome sequencing on AB 5500xl Genetic Analyzer of Blood EDTA (OT2_cohort) AB 5500 Genetic Analyzer;ABI_SOLID 1
EGAD00001003386 Whole-exome sequencing on AB 5500xl Genetic Analyzer of colorectal cancer primary tumor sample (OT2_cohort) AB 5500 Genetic Analyzer;ABI_SOLID 1
EGAD00001001012 The need for a detailed catalogue of local variability for the study of rare diseases within the context of the Medical Genome Project motivated the whole exome sequencing of 267 unrelated individuals, representative of the healthy Spanish population. AB 5500xl Genetic Analyzer; 267 fastq
EGAD00001001596 Whole Exome Sequencing data from the germline of the patient as well as the tumors in bone marrow (T-ALL), Liver (Histiocytic Sarcoma) and ileum (non-Langerhans Cell Histiocytosis). AB 5500xl Genetic Analyzer; 4 bam
EGAD00001002105 Whole-exome sequencing on AB 5500xl Genetic Analyzer of colorectal cancer metastasis sample AB 5500xl Genetic Analyzer; 16
EGAD00001002107 Whole-exome sequencing on AB 5500xl Genetic Analyzer of colorectal cancer primary tumor sample AB 5500xl Genetic Analyzer; 66
EGAD00001002104 Whole-exome sequencing on AB 5500xl Genetic Analyzer of Blood EDTA AB 5500xl Genetic Analyzer; 76
EGAD00001002106 Whole-exome sequencing on AB 5500xl Genetic Analyzer of Patient-derived xenograft derived from colorectal cancer metastasis sample AB 5500xl Genetic Analyzer; 1
EGAD00001002242 This dataset contains RNA-seq and Hi-C data files of induced pluripotent stem (iPS) cells and iPS cell-derived neural progenitors (NPCs) derived from a germline chromothripsis patient and both parents. iPS cells of the patient (cell lines 14 and 15), the father (lines 23 (with two replicates) and 32) and mother (line 30) were differentiated to NPCs and RNA was collected on day 0, day 7 and day 10 of differentiation. In addition, Hi-C data for two iPS cell-derived NPC lines from the patient (14 and 15) and two lines from the father (23 and 32) was generated. AB 5500xl Genetic Analyzer;, Illumina HiSeq 2500;, NextSeq 500;ILLUMINA 22 bam
EGAD00001000096 Pancreatic adenocarcinoma QCMG 20120201 AB SOLiD 4 System 166 bam
EGAD00001000632 AB SOLiD 4 System; 12 SOLiD_native_csfasta,SOLiD_native_qual,bam
EGAD00001000680 Single end short-read (50 bp) SOLiD 4 sequencing data for 300 individuals, constituting 100 patient-parent trios. For more details please read; http://www.nejm.org/doi/full/10.1056/NEJMoa1206524 AB SOLiD 4 System; 300 bam
EGAD00001000779 AB SOLiD 4 System; 2 bam
EGAD00001001209 To examined the reproducibility of nucleotide variant calls in replicate sequencing experiments of the same genomic DNA, we performed targeted sequencing of all known human protein kinase genes (kinome) (~3.3 Mb) using the SOLiD v4 platform. This data set contains 17 breast cancer samples that were sequenced in duplicate (n=14) or triplicate (n=3), in order to assess concordance of all calls and single nucleotide variant (SNV) calls. AB SOLiD 4 System; 37 SOLiD_native_csfasta,SOLiD_native_qual
EGAD00001000293 Sequencing data for Australian Ovarian Cancer study submitted 20121116 AB SOLiD 4 System; 72 bam
EGAD00001001385 Exome sequencing in 3 Möbius patients AB SOLiD 4 System; 3 bam
EGAD00001000323 Sequencing data for Australian Pancreatic Cancer study submitted 20130102 AB SOLiD 4 System;, Illumina HiSeq 2000; 200 bam
EGAD00001002266 The contribution of genetic predisposing factors to the development of pediatric acute lymphoblastic leukemia (ALL), the most frequently diagnosed cancer in childhood, has not been fully elucidated. Children presenting with multiple de novo leukemias are more likely to suffer from genetic predisposition. Here, we selected five of these patients and analyzed the mutational spectrum of normal and malignant tissues. AB SOLiD 4 System;ABI_SOLID, AB 5500xl Genetic Analyzer;ABI_SOLID 14 bam
EGAD00001003305 Diffuse Intrinsic Pontine Glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children with no effective treatment. To understand what drives DIPGs we integrated whole-genome-sequencing with methylation, expression and copy-number profiling. AB SOLiD System (ABI_SOLID), Illumina HiSeq 2500 (ILLUMINA) 23
EGAD00001000049 Pancreatic adenocarcinoma QCMG 20110901 AB SOLiD System 3.0, AB SOLiD 4 System 26 bam,fastq
EGAD00001000201 MDACC-endo AB SOLiD System 3.0; 28 bam
EGAD00001000115 Mutational landscapes of primary triple negative breast cancers - WGS ABI_SOLID 32 bam
EGAD00010000262 WTCCC2 project Schizophrenia (SP) samples Affyemtrix 6.0 - CHIAMO 3,019
EGAD00010000526 SNP 6.0 arrays of small cell lung cancer Affymetrics_SNP_6.0- 63
EGAD00010000546 SNP 6.0 arrays of carcinoid samples Affymetrics_SNP_6.0- 74
EGAD00010001226 UK Biobank directly genotyped dataset Affymetrix 488,377
EGAD00010001225 UK Biobank autosomal imputation dataset Affymetrix 487,409
EGAD00010000544 Cusihg's syndrome tumor samples using 250K Affymetrix 250K Nsp-GTYPE 16
EGAD00010000542 Cusihg's syndrome normal samples using 250K Affymetrix 250K Nsp-GTYPE 16
EGAD00010000714 aplastic anemia samples tumor using 250K Affymetrix 250K Nsp-GTYPE 440
EGAD00000000037 NcOEDG Stockholm 2 samples Affymetrix 5.0 514
EGAD00000000004 WTCCC1 project Coronary Artery Disease (CAD) samples Affymetrix 500K 1,998
EGAD00000000009 WTCCC1 project Type 2 Diabetes (T2D) samples Affymetrix 500K 1,999
EGAD00000000005 WTCCC1 project Inflammatory Bowel Disease (IBD) samples Affymetrix 500K 2,005
EGAD00000000007 WTCCC1 project Rheumatooid arthritis (RA) samples Affymetrix 500K 1,999
EGAD00000000001 WTCCC1 project samples from 1958 British Birth Cohort Affymetrix 500K 1,504
EGAD00000000006 WTCCC1 project Hypertension (HT) samples Affymetrix 500K 2,001
EGAD00000000003 WTCCC1 project Bipolar Disorder (BD) samples Affymetrix 500K 1,998
EGAD00000000008 WTCCC1 project Type 1 Diabetes (T1D) samples Affymetrix 500K 2,000
EGAD00000000002 WTCCC1 project samples from UK National Blood Service Affymetrix 500K 1,500
EGAD00000000036 NcOEDG Stockholm 1 samples Affymetrix 500K 484
EGAD00000000039 NcOEDG Malmo - Lund samples Affymetrix 500K 1,374
EGAD00000000016 WTCCC project Tuberculosis (TB) samples Affymetrix 500K 1,498
EGAD00000000015 WTCCC project African control samples Affymetrix 500K 1,496
EGAD00000000059 Aggregate results from 43 Carbamazepine-induced hypersensitivity syndrome patients and 1296 1958 British Birth Cohort control samples Affymetrix 500K, Illumina 610K Quad 1,339
EGAD00000000021 WTCCC2 project samples from 1958 British Birth Cohort Affymetrix 6.0 3,000
EGAD00000000025 WTCCC2 project Ulcerative Colitis (UC) samples Affymetrix 6.0 2,869
EGAD00000000119 Genotypes from cell lines derived from breast carcinoma tissue Affymetrix 6.0 51
EGAD00000000047 Signal data for from 3 recurrent and 1 ovarian primary Granulosa Cell Tumour samples Affymetrix 6.0 4
EGAD00010000950 WTCCC2 Bacteraemia Susceptibility (BS) smaples using Affymetrix 6.0 Affymetrix 6.0 4,924
EGAD00010000282 Pharmacogenomic response to Statins samples (Genotypes/Phenotypes) Affymetrix 6.0 - CHIAMO 4,134
EGAD00010000490 Affymetrix Genome-Wide Human SNP Array 6.0 data Affymetrix 6.0- 19
EGAD00010001300 Medulloblastoma expression profiling Affymetrix expression array 146
EGAD00010001301 Medulloblastoma expression profiling Affymetrix expression array 246
EGAD00010000936 Affymetrix Exon Array dataset Affymetrix GeneChip Human Exon 1.0 ST 2
EGAD00010000238 CLL Expression array Affymetrix GeneChip Human Genome U133 plus 2.0 64
EGAD00010001275 Affymetrix GeneChip® Human Transcriptome Array 2.0 Affymetrix GeneChip® Human Transcriptome Array 2.0 34
EGAD00010001273 Affymetrix GeneChip® Human Transcriptome Array 2.0 Affymetrix GeneChip® Human Transcriptome Array 2.0 34
EGAD00010000901 Russian Tuberculosis samples using Affymetrix 6.0 Affymetrix Genome-Wide Human SNP Array 6.0 Genotypes 11,937
EGAD00010000886 samples using Affymetrix HG_U133_+2 Affymetrix HG_U133_+2 99
EGAD00010001280 Transcriptome array dataset Affymetrix HG_U133_+2 25
EGAD00010001307 iOmics gene expression data using Expression Array Affymetrix Human Gene 1.0 ST Array 269
EGAD00010001414 Raw Array data from the PRAD-CA for ICGC DCC Release26 Affymetrix OncoScan FFPE Express 86
EGAD00010001196 Raw Array data from the CPCGene BRCA study Affymetrix OncoScan FFPE Express 48
EGAD00010001218 Raw Array data from the CPCGene 200PG study Affymetrix OncoScan FFPE Express 248
EGAD00010000280 CLL Expression array Affymetrix snp 6.0 4
EGAD00010000266 Metabric breast cancer samples (Genotype raw data) Affymetrix SNP 6.0 543
EGAD00010000215 Segmented (CBS) copy number aberrations (CNA); validation set Affymetrix SNP 6.0 995
EGAD00010000217 Segmented (HMM) copy number aberrations (CNA); discovery set Affymetrix SNP 6.0 997
EGAD00010000213 Segmented (CBS) copy number aberrations (CNA); discovery set Affymetrix SNP 6.0 997
EGAD00010000216 Segmented (CBS) copy number variants (CNV); validation set Affymetrix SNP 6.0 995
EGAD00010000164 Affymetrix 6.0 CEL files Affymetrix SNP 6.0 1,992
EGAD00010000214 Segmented (CBS) copy number variants (CNV); discovery set Affymetrix SNP 6.0 997
EGAD00010000050 Matched tumor-negative pancreas tissues Affymetrix SNP 6.0 15
EGAD00010000051 Cell line derived from microdissected primary pancreatic ductal adenocarcinoma tissues Affymetrix SNP 6.0 15
EGAD00010000158 Affymetrix 6.0 cel files Affymetrix SNP 6.0 1,001
EGAD00010000558 SNP 6.0 arrays of small cell lung cancer Affymetrix SNP 6.0 54
EGAD00010000942 Breast lesions assayed with Affymetrix SNP 6.0 Affymetrix SNP 6.0 125
EGAD00010001234 CN/LOH-profile of Translocation-negative FL_9 Affymetrix SNP 6.0 1
EGAD00010001238 CN/LOH-profile of Translocation-negative FL_2 Affymetrix SNP 6.0 1
EGAD00010001237 CN/LOH-profile of Translocation-negative FL_10 Affymetrix SNP 6.0 1
EGAD00010001233 CN/LOH-profile of Translocation-negative FL_5 Affymetrix SNP 6.0 1
EGAD00010001240 CN/LOH-profile of Translocation-negative FL_1 Affymetrix SNP 6.0 1
EGAD00010001236 CN/LOH-profile of Translocation-negative FL_4 Affymetrix SNP 6.0 1
EGAD00010001241 CN/LOH-profile of Translocation-negative FL_7 Affymetrix SNP 6.0 1
EGAD00010001232 CN/LOH-profile of Translocation-negative FL_8 Affymetrix SNP 6.0 1
EGAD00010001239 CN/LOH-profile of Translocation-negative FL_6 Affymetrix SNP 6.0 1
EGAD00010001235 CN/LOH-profile of Translocation-negative FL_11 Affymetrix SNP 6.0 1
EGAD00010000915 Affymetrix SNP6.0 breast cancer genome sequencing data Affymetrix SNP6.0 344
EGAD00010001079 Affymetrix SNP6.0 array breast cancer data Affymetrix SNP6.0 66
EGAD00010000252 CLL Expression Arrays Affymetrix U219 137
EGAD00010000472 CLL Expression Array Affymetrix U219 219
EGAD00010000875 CLL Expression Array Affymetrix U219 1,008
EGAD00010001202 Human genotyping data for patients infected by hepatitis C virus Affymetrix UKBiobank Array 563
EGAD00010000096 DBA case samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 27
EGAD00010000480 ccRCC case samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 240
EGAD00010000484 ccRCC control samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 234
EGAD00010000419 Han Chinese samples using Affymetrix (cases) Affymetrix_6.0 62
EGAD00010000421 Han Chinese samples using Affymetrix (controls) Affymetrix_6.0 187
EGAD00010000148 tumour samples using Affymetrix Genome-Wide SNP6.0 arrays Affymetrix_GenomeWide_SNP6.34 104
EGAD00010000452 Chondrosarcoma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6 36
EGAD00010000395 Myeloma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6 19
EGAD00010000488 Chondroblastoma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6- 7
EGAD00010000498 Affymetrix SNP6.0 genotype data for prostate cancer patients Affymetrix_SNP6- 18
EGAD00010000442 Affymetrix SNP 6.0 CEL files Affymetrix_SNP6_raw 1,302
EGAD00010000440 Segmented copy number data Affymetrix_SNP6_raw 1,302
EGAD00010000502 Case samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010000504 Control samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010000500 Case samples using U133 Plus 2.0 Array Affymetrix_U133plus2- 35
EGAD00010000462 SJLGG Case samples using Gene Expression Array Affymetrix_U133v2 75
EGAD00010001310 iOmics lipid data via mass spectrometry (MS) Agilent 1200 LC system 359
EGAD00010000937 ACGH 180K dataset Agilent 180K 5
EGAD00010000935 ACGH 244K dataset Agilent 244K 10
EGAD00010000938 mRNA Array Agilent 44K dataset Agilent 44K 16
EGAD00010001153 Family Trios on aCGH 8x60K Agilent 8x60K 138
EGAD00010000486 ccRCC case samples using expression array Agilent Human Whole Genome 4x44k v2 - Feature Extraction 101
EGAD00010000917 399 tumors profiled using Agilent miRNA microarrays (Product Number G4872A, design ID 046064). The arrays are based on miRBase release 19.0 and 2006 human miRNAs are represented. 150 ng total RNA was used as input. Agilent miRNA microarrays 399
EGAD00010000438 Normalized miRNA expression data Agilent ncRNA 60k 1,480
EGAD00010000444 Agilent ncRNA 60k txt files Agilent ncRNA 60k 1,480
EGAD00010000934 Agilent miRNA dataset Agilent SurePrint Human miRNA Microarray 2
EGAD00010000881 Digital images of ovarian cancer sections Aperio 91
EGAD00010001099 Digital images of ovarian cancer metastases Aperio 127
EGAD00010000270 Metabric breast cancer samples (Images) Aperio image - H&E stained tissue_section 564
EGAD00010001255 Autosomal STR genotypes using 15 Identifiler loci Applied Biosystems 990
EGAD00010000536 21 unlinked autosomal microsatellite loci for 30 Central Asian populations Applied Biosystems 3100 automated sequencer-GeneMarker v.1.6 (Softgenetics) 1,702
EGAD00010000538 28 unlinked autosomal microsatellite loci for 20 African and 4 philippine populations Applied Biosystems 3100 automated sequencer-GeneMarker v.1.6 (Softgenetics) 1,702
EGAD00010001155 Crohn's disease DNA samples genotyped using UK Biobank Axiom array Axiom UKB 1,676
EGAD00001000139 Tumor sample of a serious ovarian carcinoma Complete Genomics 1 CompleteGenomics_native
EGAD00001000140 Blood sample of serious ovarian carcinoma patient Complete Genomics 1 CompleteGenomics_native
EGAD00001000060 Acral melanoma study whole genomes Complete Genomics 3 CompleteGenomics_native
EGAD00001002734 Whole Genome Sequencing data set for the study "Premalignant SOX2 in ovarian cancer patients" Complete Genomics (COMPLETE_GENOMICS) 39
EGAD00010000220 Ovarian & matched normal (Genotypes) Complete Genomics - CG Build 1.4.2.8 2
EGAD00001000196 Neuroblastoma samples Complete Genomics; 203 CompleteGenomics_native
EGAD00001000641 DNA replication errors occurring in mismatch repair (MMR) deficient cells persist as mismatch mutations and predispose to a range of tumors. Here, we sequenced the first whole-genomes from MMR-deficient endometrial tumors. Complete Genomics;, Illumina HiSeq 2000; 44 CompleteGenomics_native,bam
EGAD00001000174 DATA_SET_Coverage_bias_sensitivity_of_variant_calling_for_4_WG_seq_tech Complete Genomics;, unspecified; 4 bam
EGAD00001003120 We used WGS (Complete Genomics) to characterise five metastatic tumours from a BRAF mutant melanoma patient who presented intrinsic resistance. Complete Genomics;COMPLETE_GENOMICS 6
EGAD00001003187 TBD Complete Genomics;COMPLETE_GENOMICS 9
EGAD00001003304 We collected tumor samples and adjacent nomal mucosae from 46 patients with colorectal cancer in surgical operation from 2014 to 2016 in the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) and the Research Institute of Surgery, Third Military Medical University (Chongqing, China). the qualified captured library of each sample was then loaded on Illumina HiSeq 2000 (Illumina, San Diego, CA) platforms and subjected to high-throughput sequencing. Complete Genomics;COMPLETE_GENOMICS 38
EGAD00001003310 There are 66 pairs of LAML cases(complete genomics) in this project which belongs to LAML-CN..The library is constructed by the Completes Genomics protocol. Complete Genomics;COMPLETE_GENOMICS 66
EGAD00001003593 Complete Genomics;COMPLETE_GENOMICS 24
EGAD00010000052 Monozygotic twins that are discordant for schizophrenia (Genotyping) CompleteGenomics build 1.4.2.8 - CG Build 1.4.2.8 36
EGAD00001000048 monozygotic twin discordant for schizophrenia CompleteGenomics build 1.4.2.8 - CG Build 1.4.2.8 2 CompleteGenomics_native
EGAD00010000921 samples using Affymetrix CYTOSCANHD CYTOSCANHD 12
EGAD00010001406 Breast cancer tissue and controls Exiqon 7th generation miRCURY LNA microRNA microarray system 149
EGAD00010001396 A discovery cohort of 856 adult survivors of pediatric ALL Genome-Wide Human SNP Array 6.0 - Thermo Fisher Scientific 856
EGAD00010001395 A replication cohort consisting of 1428 adult survivors of any non-ALL pediatric cancer Genome-Wide Human SNP Array 6.0 - Thermo Fisher Scientific 1,428
EGAD00010000514 Case samples using SNP 6.0 Array GenomeWideSNP_6-BirdseedV2 12
EGAD00010000510 Matched control samples using HumanOmni1-Quad GenomeWideSNP_6-BirdseedV2 12
EGAD00010000512 Case samples using HumanOmni1-Quad GenomeWideSNP_6-BirdseedV2 12
EGAD00010000508 Matched control samples using SNP 6.0 Array GenomeWideSNP_6-BirdseedV2 12
EGAD00010000470 CLL Expression Array GPL570 20
EGAD00010000425 Han Chinese samples using Immunochip HanChinese_Immunochip 192
EGAD00001001988 Cholangiocarcinoma whole genome sequencing data HiSeq X Ten (ILLUMINA), Illumina HiSeq 2000 (ILLUMINA), Illumina HiSeq 2500 (ILLUMINA) 118
EGAD00001001265 Genomic architecture of mesothelioma parent study is project 925. This project is set up in parallel to project 925 in order to Whole genome sequence ten of the 59 tumours in that project. HiSeq X Ten; 18 cram
EGAD00001001266 Whole genome sequencing of primary angiosarcoma HiSeq X Ten; 12 cram
EGAD00001001267 Anaplastic meningiomas are a rare, malignant variant of meningioma. At present there is no effective treatment for this cancer. The aim of the study is to identify somatic mutations in anaplastic meningiomas. We plan to sequence a set of 500 known cancer genes in 50 anaplastic meningioma and corresponding peripheral blood DNA samples. Bioinformatics will be used to analyse the results to assess the probability of these mutations being causal and so likely of critical importance for the tumour growth. Identification of these mutations will guide selection of appropriate compounds to effectively treat the disease. HiSeq X Ten; 60 cram
EGAD00001001271 Around 50 samples of pre-invasive lung cancer lesions showing subsequent clinical and pathological progression or regression HiSeq X Ten; 50 cram
EGAD00001001889 ***THIS DATA CAN ONLY BE USED FOR NON-COMMERCIAL CANCER RESEARCH*** Sequencing of organoid cell lines derived from oesophageal tumour sections taken from patients diagnosed with primary oesophageal cancer who underwent tumour resection surgery. HiSeq X Ten; 9 cram
EGAD00001001897 15x whole genome sequencing in samples from the Cretan Greek isolate collection HELIC MANOLIS HiSeq X Ten; 1,482 cram
EGAD00001001898 The study will investigate serial samples from the same patient taken at the time of MGUS or SMM diagnosis, and later at the time of evolution towards MM. Samples will be sequenced by whole genome along with a matched normal to obtain the highest possible amount of information toinvestigate genomic changes at disease evolution. This dataset contains all the data available for this study on 2016-01-27. HiSeq X Ten; 131 cram
EGAD00001001429 Profiling subclonal architecture and phylogeny in tumors by whole-genome sequence data mining and single-cell genome sequencing HiSeq X Ten; 2 cram
EGAD00001001440 This project entailed generation of high depth WGS (30x) of 100 individuals from the general Greek population. HiSeq X Ten; 100 cram
EGAD00001001447 Whole genome sequencing of single cell derived organoids from normal colon tissue and colorectal cancer. HiSeq X Ten; 19 cram
EGAD00001001458 Whole genome sequencing of EBV-transformed B cells in order to determine whether EBV induction of activation-induced cytidine deaminase (AID) produces genome-wide mutations and/or chromosomal rearrangements. HiSeq X Ten; 12 cram
EGAD00001001629 Whole-genome somatic rearrangement and point mutation analysis in cell lines with induced telomere fusions. HiSeq X Ten; 20 cram
EGAD00001001846 2 BRAFV600E cell lines that have been made resistance to 1. the BRAF inhibitor PLX4720 and 2. the combination therapy of dabrafenib and trametinib seem to have a internal duplication in the kinase domain. We would like to know if this is caused by a translocation. HiSeq X Ten; 4 cram
EGAD00001001634 This dataset includes the whole genomes, sequenced to high depth (30x) of 25 individuals from Papua New Guinea. The individuals were chosen from several geographically distinct Papuan groups, focusing on the highland regions: Bundi, Kundiawa, Mendi, Marawaka and Tari. HiSeq X Ten; 25 cram
EGAD00001001995 Whole genome sequencing (30X) using Hiseq X TEN on 4 HCC cell lines, primary HCCs and early-passage PDCs. HiSeq X Ten; 12 fastq
EGAD00001002227 In collaboration with Dr David Savage, we have identified a patient with a very unusual phenotype, lacking almost all visceral fat, but showing a massive accumulation of white fat tissue behind her neck and significantly elevated liver fat. Whole exome sequencing of the proband and her unaffected parents and brother has been run previously, however no causative variant has been found and the sequencing coverage was generally poor. We propose to conduct whole genome sequencing of all 4 family members at a depth of 30X. HiSeq X Ten; 3 cram
EGAD00001002146 The dataset contains the whole genome sequencing data of a family with two unaffected parents and two probands that showed Hereditary spastic paraplegias symptoms. Sequencing reads were aligned to human genome (GRCh38) using BWA-MEM, followed by indel-realignment and PCR-duplicates marking. Alignment results are available for download in BAM format. HiSeq X Ten; 4 bam
EGAD00001002198 This set of samples is composed of eight young people (7-16 years old) that have developed melanoma with first-degree relatives that have also developed cancer, which suggests a genetic component to their disease. Here we want to sequence these samples in order to find the causative mutations. As these samples do not carry any of the high-penetrance mutations known to date, finding the genes(s) responsible will offer new insights into the genetic mechanisms underlying predisposition to melanoma. HiSeq X Ten;, Illumina HiSeq 2000; 7 cram
EGAD00001001900 DNA sequencing reads of human adult stem cell cultures from liver, colon and small intestine. Including biopsy or blood samples of the donors. HiSeq X Ten;, Illumina HiSeq 2500; 55 bam
EGAD00001002719 This dataset contains whole-genome sequencing data files from colon organoid cultures, which were mutated using CRISPR-Cas9 for specific genes (APC, KRAS, TP53 and SMAD4) to generate in vitro transformed cancer cells. After introducing each mutation, the resulting cultures were subjected to whole-genome sequencing. In addition, some cultures were xenotransplanted in recipient mice. The resulting primary tumors and corresponding metastases were subjected to whole-genome sequencing. HiSeq X Ten;ILLUMINA 15 bam
EGAD00001003097 High-coverage sequencing data from 47 Yemenis samples HiSeq X Ten;ILLUMINA 47 cram
EGAD00001003168 The blood samples of eight lung cancer patients and one benign lung tumor patient are collected for this dataset. Blood samples were centrifuged first at 1,600 × g for 10 minutes, and then the plasma was transferred into new micro tubes and centrifuged at 16,000 × g for another 10 minutes. The plasma was collected and stored at -80⁰C. CfDNA was extracted from 5 ml plasma using the Qiagen QIAamp Circulating Nucleic Acids Kit and quantified by Qubit 3.0 Fluoromter (Thermo Fisher Scientific). Bisulfite conversion of cfDNA was performed by using EZ-DNA-Methylation-GOLD kit (Zymo Research). After that, Accel-NGS Methy-Seq DNA library kit (Swift Bioscience) was used to prepare the sequencing libraries. The DNA libraries were then sequenced with 150bp paired-end reads. HiSeq X Ten;ILLUMINA 9
EGAD00001003211 Deep (>25x mean coverage) whole genome sequencing on 5-10 families drawn from the Scottish Family Health Study with four or more children. HiSeq X Ten;ILLUMINA 57
EGAD00001003212 We aim to provide a powerful reference set for genome-wide association studies (GWAS) in African populations. Our pilot study to sequence 100 individuals each from Fula, Jola, Mandinka and Wollof from the Gambia to low coverage has been completed - this first part of the main effort will make available low coverage WGS data for 400 individuals from multiple ethnic groups in Burkina Faso, Cameroon, Ghana and Tanzania. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ HiSeq X Ten;ILLUMINA 74
EGAD00001003216 Whole genome sequencing of tumour normal pairs of human undifferentiated sarcomas. HiSeq X Ten;ILLUMINA 98
EGAD00001003240 Study of cell lineage and embryogenesis using biopsy samples from sites across the whole body (post mortem). Sample donors are recruited sensitively through the Phoenix study and consent to samples being taken after their death for both the Phoenix study and this WTSI study. HiSeq X Ten;ILLUMINA 33
EGAD00001003309 The study will investigate serial samples from the same patient taken at the time of MGUS or SMM diagnosis, and later at the time of evolution towards MM. Samples will be sequenced by whole genome along with a matched normal to obtain the highest possible amount of information toinvestigate genomic changes at disease evolution. This dataset contains all the data available for this study on 2017-04-27. HiSeq X Ten;ILLUMINA 139
EGAD00001003236 Raw whole genome sequence data(fastq) for the GATCI project HiSeq X Ten;ILLUMINA 10
EGAD00001003407 Whole-genome sequencing and phasing of admixed Aboriginal Australian genomes and Papua New Guinean genomes using 10x Genomics Chromium technology. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/ This dataset contains all the data available for this study on 2017-06-27. HiSeq X Ten;ILLUMINA 4
EGAD00001003445 Clear cell renal cancer is characterized by near-universal loss of the short arm of chromosome 3 (3p). This event arises through unknown mechanisms, but critically results in the loss of several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear cell renal cancer (ccRCC) recruited into the Renal TRACERx study. We find novel hotspots of point mutations in the 5'-UTR of TERT, targeting a MYC-MAX repressor, that result in telomere lengthening. The most common structural abnormality generates simultaneous 3p loss and 5q gain (36% patients), typically through chromothripsis. Using molecular clocks, we estimate this occurs in childhood or adolescence, generally preceding emergence of the most recent common ancestor by years to decades. Similar genomic changes recent common ancestor by years to decades. Similar genomic changes are seen in inherited kidney cancers. Modeling differences in age-incidence between inherited and sporadic cancers suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred. Targeting essential genes in deleted regions of chromosome 3p could represent a potential preventative strategy for renal cancer. HiSeq X Ten;ILLUMINA 164
EGAD00001003446 This dataset includes deep coverage (>60x) whole exomes of 15 human embryonic stem cell lines. Genomic DNA was purified and fragmented using the Illumina Nextera system for library preparation and sequenced using 150bp paired-end reads. Sequencing reads were aligned to the hg19 reference genome using the BWA MEM alignment program. HiSeq X Ten;ILLUMINA 15
EGAD00001003512 This dataset includes bam files from 58 samples. These bam files include all read pairs where at least one of the reads aligns within 1kb of the HTT repeat expansion. These samples were sequenced using 2x150bp reads on an Illumina HiSeqX sequencer and aligned using bwa. Twelve of the samples used TruSeq Nano library preparation and 46 samples used TruSeq DNA PCR-free sample preparation. HiSeq X Ten;ILLUMINA 58
EGAD00001003478 A IPS06_X_ENeuron_WGBS paired end data for Early neuron cells(Tuj1) HiSeq X Ten;ILLUMINA 1
EGAD00001003480 A OB57_D_PreA_WGBS paired end data for Preadipocyte(fat) HiSeq X Ten;ILLUMINA 1
EGAD00001003472 A DB31_N_Alpha_WGBS paired end data for alpha cells(PSA-NCAM(-), pancreas) HiSeq X Ten;ILLUMINA 1
EGAD00001003471 A CKD27_C_Mesan_WGBS paired end data for Mesangial cells(kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003477 A IPS05_X_NPC_WGBS paired end data for Neural progenitor cells(Nestin) HiSeq X Ten;ILLUMINA 1
EGAD00001003475 A IPS03_N_ENeuron_WGBS paired end data for Early neuron cells(Tuj1) HiSeq X Ten;ILLUMINA 1
EGAD00001003479 A OB56_N_PreA_WGBS paired end data for Preadipocytes(fat) HiSeq X Ten;ILLUMINA 1
EGAD00001003474 A IPS02_N_NPC_WGBS paired end data for Neural progenitor cells(Nestin) HiSeq X Ten;ILLUMINA 1
EGAD00001003476 A IPS04_X_Fibroblast_WGBS paired end data for iPSC(Oct4) HiSeq X Ten;ILLUMINA 1
EGAD00001003469 A CKD24_C_Podo_WGBS paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003473 A IPS01_N_Fibroblast_WGBS paired end data for iPSC(Oct4) HiSeq X Ten;ILLUMINA 1
EGAD00001003468 A CKD23_C_Mesan_WGBS paired end data for Mesangial cells(kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003470 A CKD25_C_Podo_WGBS paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003510 BAM files with sequencing reads derived from Illumina whole genome sequencing of two DNA samples from lymphoblastoid cell lines from two patients with congenital disease. Whole genome sequencing was performed using Illumina HiSeq X Ten and samples were prepared using TruSeq library prep. HiSeq X Ten;ILLUMINA 2
EGAD00001003562 This dataset includes bam files from 120 samples. These samples were sequenced using 2x150bp reads on an Illumina HiSeqX sequencer and aligned using the Isaac aligner. All samples were processed with TruSeq DNA PCR-free sample preparation. HiSeq X Ten;ILLUMINA 120
EGAD00001003439 Three files of patients 10, 11 and 13 with WGS done on Illumina HiSeq X Ten. For research purpose and authorised user only. HiSeq X Ten;ILLUMINA 3
EGAD00001003440 One file of patient 16 with WGS done on Illumina HiSeq X-Ten. For research purpose and authorised user only. HiSeq X Ten;ILLUMINA 1
EGAD00001002696 Recurrent breast cancer is almost universally fatal. We characterize 170 patients locally relapsed or distant metastatic cancers using massively parallel sequencing. We identify that the relapse-seeding clone disseminates late from the primary tumor. TP53 and AKT1 appear to be enriched in ER-positive cancers predisposed to relapse. Mutation acquisition continues at relapse as the same mutation signatures continue to operate and new signatures, such as that caused by radiotherapy appear de novo. In 49% of cases we identify drivers mutations private to the relapse and these are sampled from a wider range of cancer genes, including SWI-SNF complex and JAK-STAT signaling. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2000;ILLUMINA 60 bam,cram
EGAD00001003513 This dataset includes bam files from 3,001 samples. These bam files include all read pairs where at least one of the reads aligns within 1kb of the C9orf72 repeat expansion. Additionally, these bam files also contain reads that are aligned to any of 29 pre-determined off target locations where the aligners are known to mis-align reads associated with this repeat expansion. These samples were sequenced using a combination of 2x100bp reads on an Illumina HiSeq2000 and 2x150bp reads on an Illumina HiSeqX sequencer and aligned using the Isaac aligner. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2000;ILLUMINA 3,001
EGAD00001003315 This dataset includes the high-throughput sequencing data from a study entitled "Clonal History and Genetic Predictors of Transformation into Small Cell Carcinomas from Lung Adenocarcinomas". Whole-genome sequencing libraries were generated by PCR-free methods, and sequencing run was made in HiSeq X or HiSeq 2500 machines. PCR duplicates-marked, indel-realigned, and base-recalibrarted BAM files are provided in our dataset. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 15
EGAD00001003261 These are seven sequencing files form whole exome and whole genome of five tissue samples collected from one pancreatic cancer patient HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 5
EGAD00001002742 Whole-genome sequencing data from Chad and Lebanon. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 15 cram
EGAD00001003117 In this study, we sequenced three NUT midline carcinoma genomes and their transcriptomes (NMC1, NMC2 and Ty-82), and two paired normal blood samples (for NMC1 and NMC2). Whole-genome sequencing libraries were generated by PCR-free methods, and sequencing run was made in HiSeq X machines. Transcriptome (mRNA) sequencing was performed in HiSeq 2500 machines. PCR duplicates-marked, indel-realigned, and base-recalibrarted BAM files are provided in our dataset. HiSeq X Ten;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 8
EGAD00001003751 Whole genome sequencing data for primary tumors, matching control material from blood and their corresponding organoid. Whole transcriptome data for organoids. HiSeq X Ten;ILLUMINA, NextSeq 500;ILLUMINA 102
EGAD00000000120 WTCCC2 project Multiple Sclerosis (MS) samples Human670-QuadCustom v1 11,375
EGAD00010000963 Healthy volunteers recruited in Samoa HumanCore-24 BeadChip 24
EGAD00010000959 Healthy volunteers recruited in Fiji HumanCore-24 BeadChip 854
EGAD00010000961 Rheumatic heart disease cases recruited in Fiji HumanCore-24 BeadChip 535
EGAD00010000953 Healthy adult volunteers and newborns recruited in various countries across Oceania. HumanCore-24 BeadChip 937
EGAD00010000957 Rheumatic heart disease cases recruited in New Caledonia HumanCore-24 BeadChip 465
EGAD00010000960 Definite and borderline rheumatic heart disease cases and patients with mild non-diagnostic valvulopathy recruited in Samoa HumanCore-24 BeadChip 126
EGAD00010000954 Healthy volunteers recruited in New Caledonia HumanCore-24 BeadChip 356
EGAD00010000516 Samples from the Pomak Villages in Greece, Pomak isolate HumanExome_12v1.1_A -GenCall, zCall 1,046
EGAD00010000518 Samples from the Greek island of Crete, MANOLIS cohort HumanExome_12v1.1_A -GenCall, zCall 1,280
EGAD00010000377 DNA methylation analysis of 6 primary lymphoma samples HumanMethylation450k Bead Chip - Genome Studio 6
EGAD00010000379 DNA methylation analysis of 2 peripheral blood samples HumanMethylation450k Bead Chip - Genome Studio 2
EGAD00010000427 DNA methylation analysis of 4 peripheral blood samples HumanMethylation450k Bead Chip - Genome Studio 4
EGAD00010000429 DNA methylation analysis of 4 primary lymphoma samples HumanMethylation450k Bead Chip - Genome Studio 4
EGAD00010000908 Illumina SNP-arrays for matching retinoblastoma-blood pairs and retinoblastoma cell lines. HumanOmni1 Quad BeadChip 132
EGAD00010000919 samples using Illumina HUMANOMNI1QUAD HUMANOMNI1QUAD 2
EGAD00010000920 samples using Illumina HUMANOMNIEXPRESS HUMANOMNIEXPRESS 50
EGAD00010001281 SNP array dataset HUMANOMNIEXPRESS 50
EGAD00010000522 Samples from the Greek island of Crete, MANOLIS cohort HumanOmniExpress-12 v1.1 BeadChip-GenCall 1,364
EGAD00010000958 Healthy volunteers recruited in Fiji with higher density genotyping HumanOmniExpressExome-8 BeadChip 32
EGAD00010000962 Healthy volunteers and missing phenotype individuals recruited in New Caledonia with higher density genotyping HumanOmniExpressExome-8 BeadChip 30
EGAD00010000955 Rheumatic heart disease cases recruited in Fiji with higher density genotyping HumanOmniExpressExome-8 BeadChip 32
EGAD00010000956 Rheumatic heart disease cases recruited in New Caledonia with higher density genotyping HumanOmniExpressExome-8 BeadChip 34
EGAD00010000940 Gambian specimens with trachomatous scarring WHO grade C2/C3 Illiumina Omni 2.5 1,531
EGAD00010001032 RNA Expression using Illumina HT12 v3 Illlumina HT12 v3 153
EGAD00010000144 Healthy volunteer collection of European Ancestry Illumin OmniExpress v1.0 - Illumina GenomeStudio 288
EGAD00010000476 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 1 (CC1) Illumina 110
EGAD00010000474 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 2 (CC2) Illumina 98
EGAD00010000478 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 3 (CC3) Illumina 118
EGAD00010001332 HipSci - Bardet-Biedl Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010000773 HipSci - Healthy Normals - Genotyping Array - November 2014 Illumina 580
EGAD00010000892 Healthy individuals from Italy Illumina 300
EGAD00010000909 HipSci - Embryonic Stem Cells - Methylation Array - April 2016 Illumina 2
EGAD00010000775 HipSci - Healthy Normals - Expression Array - November 2014 Illumina 580
EGAD00010000910 HipSci - Embryonic Stem Cells - Expression Array - April 2016 Illumina 2
EGAD00010000911 HipSci - Embryonic Stem Cells - Genotyping Array - April 2016 Illumina 2
EGAD00010001330 HipSci - Healthy Normals - Expression Array - July 2017 Illumina 1
EGAD00010001139 HipSci - Healthy Normals - Methylation Array - October 2016 Illumina 181
EGAD00010001145 HipSci - Bardet-Biedl Syndrome - Methylation Array - October 2016 Illumina 45
EGAD00010001143 HipSci - Healthy Normals - Expression Array - September 2016 Illumina 613
EGAD00010001147 HipSci - Healthy Normals - Genotyping Array - September 2016 Illumina 613
EGAD00010001149 HipSci - Monogenic Diebetes - Methylation Array - October 2016 Illumina 35
EGAD00010001427 Cardio-Metabochip genotypes for B99 cohort Illumina 1,336
EGAD00010001433 Illumina HumanMethylation450 BeadChip Illumina 162
EGAD00010001428 Cardio-Metabochip genotypes for IHIT cohort Illumina 2,791
EGAD00010001340 HipSci - Bardet-Biedl Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001344 HipSci - Hereditary Cerebellar Ataxias - Genotyping Array - July 2017 Illumina 1
EGAD00010001342 HipSci - Monogenic Diabetes - Expression Array - July 2017 Illumina 1
EGAD00010001328 HipSci - Healthy Normals - Genotyping Array - July 2017 Illumina 0
EGAD00010001334 HipSci - Monogenic Diabetes - Genotyping Array - July 2017 Illumina 1
EGAD00010001346 HipSci - Hereditary Spastic Paraplegia - Genotyping Array - July 2017 Illumina 1
EGAD00010001348 HipSci - Kabuki Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010001350 HipSci - Usher Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010001352 HipSci - Alport Syndrome - Genotyping Array - July 2017 Illumina 1
EGAD00010001354 HipSci - Congenital Hyperinsulinia - Genotyping Array - July 2017 Illumina 1
EGAD00010001360 HipSci - Bleeding and Platelet Disorders - Genotyping Array - July 2017 Illumina 1
EGAD00010001362 HipSci - Macular Dystrophy - Genotyping Array - July 2017 Illumina 1
EGAD00010001364 HipSci - Retinitis Pigmentosa - Genotyping Array - July 2017 Illumina 1
EGAD00010001366 HipSci - Battens Disease - Genotyping Array - July 2017 Illumina 1
EGAD00010001368 HipSci - Hereditary Cerebellar Ataxias - Expression Array - July 2017 Illumina 1
EGAD00010001370 HipSci - Hereditary Spastic Paraplegia - Expression Array - July 2017 Illumina 1
EGAD00010001372 HipSci - Kabuki Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001376 HipSci - Alport Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001378 HipSci - Congenital Hyperinsulinia - Expression Array - July 2017 Illumina 1
EGAD00010001380 HipSci - Hypertrophic Cardiomyopathy - Expression Array - July 2017 Illumina 1
EGAD00010001382 HipSci - Primary Immune Deficiency - Expression Array - July 2017 Illumina 1
EGAD00010001384 HipSci - Bleeding and Platelet Disorders - Expression Array - July 2017 Illumina 1
EGAD00010001386 HipSci - Macular Dystrophy - Expression Array - July 2017 Illumina 1
EGAD00010001388 HipSci - Retinitis Pigmentosa - Expression Array - July 2017 Illumina 1
EGAD00010001390 HipSci - Battens Disease - Expression Array - July 2017 Illumina 1
EGAD00010001356 HipSci - Hypertrophic Cardiomyopathy - Genotyping Array - July 2017 Illumina 1
EGAD00010001358 HipSci - Primary Immune Deficiency - Genotyping Array - July 2017 Illumina 1
EGAD00010001374 HipSci - Usher Syndrome - Expression Array - July 2017 Illumina 1
EGAD00010001418 HumanOmni25M-8v1-1 Illumina 24
EGAD00010001283 Illumina HumanOmni5-Quad BeadChips Illumina 229
EGAD00010001177 This dataset contains 61 tumors SNP-array dataset from 15 EGFR mutant lung adenocarcinoma patients. Illumina 61
EGAD00010001176 This dataset contains 15 control SNP-array dataset from 15 EGFR mutant lung adenocarcinoma patients. Illumina 15
EGAD00010000284 NBS control samples only (Hap300) Illumina (Various) 2,500
EGAD00010000286 All cases and controls (Hap550) Illumina (various) 11,950
EGAD00000000022 WTCCC2 project samples from 1958 British Birth Cohort Illumina 1.2M 3,000
EGAD00010000383 MRCA sample using 100K Illumina 100K - GenomeStudio 394
EGAD00000000011 WTCCC1 project Autoimmune Thyroid Disease (ATD) samples Illumina 15K 900
EGAD00000000014 WTCCC1 project samples from 1958 British Birth Cohort Illumina 15K 1,504
EGAD00000000010 WTCCC1 project Ankylosing Spondylitis (AS) samples Illumina 15K 957
EGAD00000000012 WTCCC1 project Multiple Sclerosis (MS) samples Illumina 15K 975
EGAD00000000013 WTCCC1 project Breast cancer (BC) samples Illumina 15K 1,004
EGAD00010000939 Illumina 1M SNP Array dataset Illumina 1M SNP Array 2
EGAD00010000951 SNP array data for 668 cancer cell lines Illumina 2.5M 668
EGAD00010001309 iOmics genomic data using 2.5M and Exome array Illumina 2.5M and Illumina Exome array 323
EGAD00010000130 Cerebellar ataxia, mental retardation, and disequilibrium syndrome (CAMRQ) samples Illumina 300 Duo V2 - Bead Studio, Illumina 2
EGAD00010000381 MRCE sample using 300K Illumina 300K - GenomeStudio 543
EGAD00010000946 Human samples, 450k analysis Illumina 450k 127
EGAD00010000916 BASIS breast cancer DNA methylation Illumina 450k Illumina 450k 457
EGAD00010001001 Primary renal cell carcinoma (RCC), RCC metastases and cell lines by Illumina 450K Illumina 450K 62
EGAD00010001025 BLUEPRINT DNA methylation profiles of monocytes, T cells and B cells in type 1 diabetes-discordant monozygotic twins Illumina 450K 302
EGAD00010001162 Oncotrack primary tumor samples using 450K. The dataset includes shared AF analysis files oncotrackDNAmAnalysis.R and oncotrackDNAmBetaScores.txt which were applied for both Oncotrack_450K_tumor (EGAD00010001162) and Oncotrack_450K_metastatic (EGAD00010001161) datasets. Illumina 450K 67
EGAD00010001161 Oncotrack metastatic samples using 450K. The shared AF analysis files oncotrackDNAmAnalysis.R and oncotrackDNAmBetaScores.txt which were applied for both Oncotrack_450K_tumor (EGAD00010001162) and Oncotrack_450K_metastatic (EGAD00010001161) datasets are included on Oncotrack_450K_tumor (EGAD00010001162) dataset. Illumina 450K 15
EGAD00010001294 Methylation data using 450K Illumina 450k 1,128
EGAD00010001261 DNAm Case samples using Illumina Infinium 450K Illumina 450K array 33
EGAD00010001262 DNAm Case samples using Illumina Infinium 450K Illumina 450K array 32
EGAD00010001260 DNAm Case samples using Illumina Infinium 450K Illumina 450K array 33
EGAD00010001003 This data set contains two data files. First data file (file name: PREDO_GA_EGA_methylation_data.csv) includes methylation data from 485512 sites accross human genome from 96 individuals acquired from Illumina 450K -chip. The other data file (file name: PREDO_GA_EGA_phenotypes.csv) contains the gestation ages and the genders of the 96 samples. Illumina 450K-chip (methylation data) 96
EGAD00010000464 Down syndrome SNP genotyping data Illumina 550K - Illumina Genome Studio 338
EGAD00000000026 Randomly-selected, unrelated individuals Illumina 610-Quad 518
EGAD00010000912 SEA 610K Illumina 610K 1
EGAD00000000057 WTCCC project samples from the Parkinson's disase cohort Illumina 610K Quad 1,705
EGAD00000000056 WTCCC project samples from the primary biliary cirrhosis cohort Illumina 610K Quad 1,705
EGAD00000000060 Samples from the UK Glomerulonephritis DNA bank Illumina 610K Quad, Illumina Hap300 1,705
EGAD00010000913 SEA 660K Illumina 660K 3
EGAD00010000867 Expression Arrays Illumina beadarray 16
EGAD00010000868 Targeted bisulfite sequencing Illumina Bisulfite-Sequencing 16
EGAD00010000860 Pol2 Illumina ChIP-Sequencing 16
EGAD00010000859 Smad3 Illumina ChIP-Sequencing 16
EGAD00010000863 H3K27Ac Illumina ChIP-Sequencing 16
EGAD00010000862 H3K27me3 Illumina ChIP-Sequencing 16
EGAD00000000035 NcOEDG Helsinki 4 samples Illumina CNV370 693
EGAD00000000115 Summary data from GWAS analysis on 856 cases and 2836 control Illumina CytoSNP-12 3,719
EGAD00010001075 Argentine samples using 250K Illumina Exome 250K 391
EGAD00001000100 Renal Matched Pair Cell Line Exome Sequencing Illumina Genome Analyzer II 10 bam
EGAD00001000026 Investigation of the genetic basis of the rare syndrome Post-Transfusion Purpura (PTP) Illumina Genome Analyzer II 5 bam,srf
EGAD00001000094 Cancer Genome Libraries Tests Illumina Genome Analyzer II 16 bam
EGAD00001000003 Gencode Exome Pilot Illumina Genome Analyzer II 7 srf
EGAD00001000092 Cancer Exome Resequencing Illumina Genome Analyzer II 58 bam
EGAD00001000104 Acute Lymphoblastic Leukemia Exome sequencing 2 Illumina Genome Analyzer II 97 bam
EGAD00001000095 Acute Myeloid Leukemia Sequencing Illumina Genome Analyzer II 9 bam
EGAD00001000089 Acute Lymphoblastic Leukemia Exome sequencing Illumina Genome Analyzer II 20 bam
EGAD00001000018 Identifying causative mutations for Thrombocytopenia with Absent Radii Illumina Genome Analyzer II 5 bam
EGAD00001000024 Whole Exome Sequencing for Characterization of Disease Causing Mutations in two Pakistani Families Suffering from Autosomal Recessive Ocular Disorders. Illumina Genome Analyzer II 4 srf
EGAD00001000111 CML Discovery Project Illumina Genome Analyzer II 6 bam
EGAD00001000029 Grey Platelet Syndrome (GPS) Illumina Genome Analyzer II 5 srf
EGAD00000000055 COLO-829 is a publicly available immortal cancer cell line and COLO-829BL is a lymphoblastoid cell line derived from the same patient Illumina Genome Analyzer II 2
EGAD00001000040 Bleeding Illumina Genome Analyzer II 6 bam
EGAD00001000058 Exome Sequencing analysis Illumina Genome Analyzer II 21 Illumina_native_qseq
EGAD00001000057 RNA-Seq analysis Illumina Genome Analyzer II 15 Illumina_native_qseq
EGAD00001000063 Triple Negative Breast Cancer sequencing Illumina Genome Analyzer II 6 bam
EGAD00000000053 Sequencing data from Breast Cancer samples Illumina Genome Analyzer II 1
EGAD00001000102 Myeloproliferative Disorder Sequencing Illumina Genome Analyzer II 6 bam
EGAD00001000098 FRCC Exome sequencing Illumina Genome Analyzer II 16 bam
EGAD00001000034 "Usage of small amounts of DNA for Illumina sequencing" Illumina Genome Analyzer II 3 bam
EGAD00001000035 "Single nucleotide variant detection in multiple foci of three prostate cancer tumors" Illumina Genome Analyzer II 9 bam
EGAD00001000033 "SNV detection from formalin fixed paraffin embedded (FFPE) samples" Illumina Genome Analyzer II 6 bam
EGAD00001000036 "Copy number variant detection in multiple foci of three prostate cancer tumors" Illumina Genome Analyzer II 9 bam
EGAD00000000051 Sequencing data from matching Renal Carcinoma samples Illumina Genome Analyzer II 25
EGAD00001000090 Glioma cell lines rearrangement screen Illumina Genome Analyzer II 3 bam
EGAD00000000114 Whole transcriptome sequence data from 18 ovarian clear-cell carcinoma samples and one TOV21G ovarian clear-cell carcinoma cell line Illumina Genome Analyzer II 1
EGAD00001000031 Human Colorectal Cancer Exome Sequencing Illumina Genome Analyzer II 16 srf
EGAD00001000038 Hyperfibrinolysis Illumina Genome Analyzer II 5 bam
EGAD00001000093 Breast Cancer Exome Resequencing Illumina Genome Analyzer II 21 bam
EGAD00001000091 Non Tumour Renal Cell Line Sequencing Illumina Genome Analyzer II 1 bam
EGAD00001000037 An evaluation of different strategies for large-scale pooled sequencing study design. Illumina Genome Analyzer II 7 bam,srf
EGAD00001000013 CLL Cancer Whole Genome Sequencing Illumina Genome Analyzer II 19 srf
EGAD00001000059 Screening for human epigenetic variation at CpG islands Illumina Genome Analyzer II 116 bam
EGAD00001000041 Various Platelet Disorders Illumina Genome Analyzer II 7 bam
EGAD00001000064 Cell Line Sub Clone Rearrangement Screen Illumina Genome Analyzer II 6 bam
EGAD00001000097 Matched breast cancer fusion gene study Illumina Genome Analyzer II 46 bam,srf
EGAD00001000066 Breast Cancer Follow Up Series Illumina Genome Analyzer II 288 bam
EGAD00001000105 MuTHER adipose tissue small RNA expression Illumina Genome Analyzer II 130 bam
EGAD00001000103 Myeloproliferative Disorder Sequencing Illumina Genome Analyzer II 4 bam
EGAD00001000019 Lethal malformation syndrome Illumina Genome Analyzer II 6 srf
EGAD00001000112 Identifying Novel Fusion Genes in Myeloma Illumina Genome Analyzer II 6 bam
EGAD00001000099 Meningioma Exome Illumina Genome Analyzer II 26 bam
EGAD00001000065 Mixed Leukemia Rearrangement Screen Illumina Genome Analyzer II 5 bam
EGAD00000000046 RNA-SEQ data from 3 recurrent and 1 ovarian primary Granulosa Cell Tumour samples Illumina Genome Analyzer II 4
EGAD00000000045 Genomic sequencing and transcriptome shotgun sequencing of a metastatic tumour and its recurrence after drug therapy in a single patient Illumina Genome Analyzer II 1
EGAD00000000048 Sequencing data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample Illumina Genome Analyzer II 1
EGAD00000000049 RNA-SEQ data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample Illumina Genome Analyzer II 1
EGAD00001000088 ER-, HER2-, PR- breast Cancer genome sequencing Illumina Genome Analyzer II 6 bam
EGAD00000000052 Sequencing data from natching Pancreatic Carcinoma samples Illumina Genome Analyzer II 25
EGAD00001000025 Determination of the molecular nature of the Vel blood group by exome sequencing Illumina Genome Analyzer II 4 srf
EGAD00001000022 Exome sequencing in patients with cardiac arrhythmias Illumina Genome Analyzer II 20 srf
EGAD00001000050 Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes Illumina Genome Analyzer II 13 bam
EGAD00001000084 Matched Ovarian Cancer Sequencing Illumina Genome Analyzer II 23 bam
EGAD00001000004 CLL cancer Sample Sequencing Illumina Genome Analyzer II, Illumina Genome Analyzer 5 srf
EGAD00001000101 ADCC Exome Sequencing Illumina Genome Analyzer II, Illumina HiSeq 2000; 125 bam
EGAD00001000118 Osteosarcoma Exome Sequencing